Institutes
Refine
Year of publication
- 2021 (667) (remove)
Document Type
- Article (618)
- Preprint (32)
- Conference Proceeding (11)
- Doctoral Thesis (6)
Language
- English (667) (remove)
Has Fulltext
- yes (667) (remove)
Is part of the Bibliography
- no (667)
Keywords
- SARS-CoV-2 (23)
- COVID-19 (20)
- inflammation (12)
- prostate cancer (9)
- autophagy (8)
- Epilepsy (7)
- survival (7)
- ADHD (6)
- breast cancer (6)
- radical prostatectomy (6)
- tumor microenvironment (6)
- Genetics (5)
- aging (5)
- apoptosis (5)
- children (5)
- endothelial cells (5)
- mortality (5)
- outcome (5)
- risk factors (5)
- Cancer (4)
- Heart failure (4)
- Immunotherapy (4)
- Neurology (4)
- ROS (4)
- Risk factors (4)
- acute myeloid leukemia (4)
- angiogenesis (4)
- chemotherapy (4)
- cirrhosis (4)
- epilepsy (4)
- extracellular matrix (4)
- gene therapy (4)
- hypoxia (4)
- iron (4)
- iron deficiency (4)
- oxidative stress (4)
- prevalence (4)
- stroke (4)
- targeted therapy (4)
- vaccination (4)
- 177Lu-PSMA-617 (3)
- Acute myeloid leukemia (3)
- Alcohol (3)
- Angiogenesis (3)
- Apoptosis (3)
- Biochemistry (3)
- Bipolar disorder (3)
- Cell biology (3)
- Diagnostic markers (3)
- EEG (3)
- Edema (3)
- Immunology (3)
- IntelliCage (3)
- Medical research (3)
- Melanoma (3)
- Microbiology (3)
- Molecular biology (3)
- Mortality (3)
- NK cells (3)
- Outcome (3)
- PSMA (3)
- Proteomics (3)
- Quality of life (3)
- Radiotherapy (3)
- Seizure (3)
- Surgery (3)
- Survival (3)
- VEGF (3)
- adverse events (3)
- biomarker (3)
- bladder cancer (3)
- cancer (3)
- data science (3)
- dentate gyrus (3)
- epidemiology (3)
- exosomes (3)
- external beam radiotherapy (3)
- fMRI (3)
- glioblastoma (3)
- haemophilia care (3)
- haemophilia treatment (3)
- immune cells (3)
- immunotherapy (3)
- influenza (3)
- liver (3)
- liver cirrhosis (3)
- lung cancer (3)
- macrophage polarization (3)
- macrophages (3)
- metastasis (3)
- metastatic prostate cancer (3)
- pediatric (3)
- proliferation (3)
- toll-like receptor (3)
- treatment (3)
- treatment centres (3)
- 3D printing (2)
- ALK (2)
- Acuris (2)
- Acute lymphoblastic leukemia (2)
- Adenocarcinoma (2)
- Age estimation (2)
- Anemia (2)
- Angiography (2)
- Ataxia-telangiectasia (2)
- Attitude (2)
- Autopsy (2)
- BAG3 (2)
- BCOR (2)
- BPH (2)
- Bacterial infection (2)
- Behavior (2)
- Blood (2)
- Blood loss estimation (2)
- Blow flies (2)
- Bone density (2)
- Bone marrow (2)
- Brain (2)
- Breast cancer (2)
- Burden of illness (2)
- CD14 (2)
- COVID 19 (2)
- CRM (2)
- CSM (2)
- Cancer-specific mortality (2)
- Cardiovascular diseases (2)
- Cell culture (2)
- Cesarean section (2)
- Chronic kidney disease (2)
- Cirrhosis (2)
- Collagen (2)
- Corona (2)
- DMEK (2)
- Dental implant (2)
- Depression (2)
- Dravet syndrome (2)
- ER stress (2)
- EWSR1 (2)
- Endocannabinoid (2)
- Endocrinology (2)
- Entscheidungsassistenz (2)
- Environmental support (2)
- Epidemiology and End Results (2)
- Fasting (2)
- Forensic medicine (2)
- Gene fusion (2)
- Gene regulation (2)
- Gleason score (2)
- Glioblastoma (2)
- Glucose (2)
- Health care (2)
- Healthcare costs (2)
- Human behaviour (2)
- Hypertension (2)
- Induction chemotherapy (2)
- Infection (2)
- Inflammation (2)
- Intensive care treatment (2)
- Intensive care units (2)
- Interleukin-6 (2)
- Ketogenic diet (2)
- Labor and delivery (2)
- Leptin (2)
- MRI (2)
- Machine learning (2)
- Medical consultation (2)
- Medical risk factors (2)
- Model (2)
- Multidetector computed tomography (2)
- NADH dehydrogenase (2)
- NADPH oxidase (2)
- NCCN (2)
- NF-κB (2)
- Neuroscience (2)
- Osteoporosis (2)
- PCR (2)
- Pandemic (2)
- Pathogenesis (2)
- Patient blood management (2)
- Patient needs (2)
- Patientenbedürfnisse (2)
- Pediatric (2)
- Penile cancer (2)
- Periodontal treatment (2)
- Person-Umwelt-Passung (2)
- Person-environment fit (2)
- Physical activity (2)
- Physiology (2)
- Platelet-rich fibrin (2)
- Point-of-care testing (2)
- Portal hypertension (2)
- Post-mortem interval (2)
- Pregnancy (2)
- Preterm birth (2)
- Prevalence (2)
- Prognostic tool (2)
- Prophylaxis (2)
- Prostate cancer (2)
- Pulmonary embolism (2)
- Radiation (2)
- Rare diseases (2)
- Research Article (2)
- SCC (2)
- SV2A (2)
- Sensitivity (2)
- Specificity (2)
- Spine (2)
- Squamous cell carcinoma (2)
- Status epilepticus (2)
- Suicide (2)
- Supported decision making (2)
- Surveillance (2)
- Systemic inflammation (2)
- Systemic therapy (2)
- TSC (2)
- Tomography (x-ray computed) (2)
- Tooth loss (2)
- Trauma (2)
- Treatment (2)
- Treatment outcome (2)
- Ultrasound (2)
- Undergraduate medical education (2)
- Unterstützung der Umwelt (2)
- Usability (2)
- Variant histology (2)
- Visual estimation (2)
- alcohol use disorder (2)
- anemia (2)
- animal experiments (2)
- antibiotic resistance (2)
- antiviral therapy (2)
- bibliometrics (2)
- biomarkers (2)
- biopsy cores (2)
- bleeding (2)
- bortezomib (2)
- brain cancer (2)
- cancer-specific mortality (2)
- cell cycle (2)
- cell migration (2)
- cerebrospinal fluid (2)
- cesarean section (2)
- child (2)
- childhood acute myeloid leukemia (2)
- chronic kidney disease (2)
- clinical trial (2)
- clinical trials (2)
- colon cancer (2)
- complexome profiling (2)
- computed tomography (2)
- contemporary (2)
- coronavirus (2)
- critical care (2)
- dexamethasone (2)
- diabetes (2)
- diabetes mellitus (2)
- diagnostic algorithm (2)
- drug resistance (2)
- efficacy (2)
- elderly (2)
- electrophysiology (2)
- epigenetics (2)
- epithelial to mesenchymal transition (2)
- ergonomics (2)
- executive function (2)
- extracellular vesicles (2)
- fibroblasts (2)
- follow-up (2)
- furcation involvement class III (2)
- fusion biopsy (2)
- heart (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- homeostatic plasticity (2)
- innate immunity (2)
- intermediate risk (2)
- iron metabolism (2)
- kidney (2)
- kidney cancer (2)
- levetiracetam (2)
- lipocalin-2 (2)
- liver transplantation (2)
- lncRNA (2)
- localized prostate cancer (2)
- long-term tooth survival (2)
- lymph node dissection (2)
- machine learning (2)
- macrophage (2)
- magnetic resonance imaging (2)
- mast cells (2)
- metastatic castration-resistant prostate cancer (2)
- miRNA (2)
- microRNA (2)
- microglia (2)
- multiple sclerosis (2)
- ncRNA (2)
- neurocognitive (2)
- neuropathic pain (2)
- neutralizing antibodies (2)
- niche (2)
- oligomerisation (2)
- osteoarthritis (2)
- other-cause mortality (2)
- out-patient paediatrics (2)
- overall survival (2)
- oxidative phosphorylation (2)
- p53 (2)
- pain (2)
- patients (2)
- pediatric patients (2)
- pentose phosphate pathway (2)
- perception (2)
- periodontitis stage III and IV (2)
- pharmacokinetics (2)
- phosphorylation (2)
- platelets (2)
- pneumonia (2)
- portal hypertension (2)
- primary care (2)
- primary cilium (2)
- primary prostate cancer (2)
- questionnaire (2)
- radical prostatecomy (2)
- radiotherapy (2)
- receptor (2)
- refractory (2)
- regenerative medicine (2)
- relapse (2)
- residual myometrial thickness (2)
- respiratory chain (2)
- respiratory tract infection (2)
- salvage therapy (2)
- second-line (2)
- seizure (2)
- spine head (2)
- status epilepticus (2)
- strength training (2)
- stress (2)
- stress granules (2)
- supportive periodontal therapy (2)
- surgery (2)
- synaptic plasticity (2)
- synaptopodin (2)
- systematic biopsy (2)
- systemic antibiotics (2)
- thrombolysis (2)
- thrombosis (2)
- tissue engineering (2)
- tooth loss (2)
- triple-negative breast cancer (2)
- tumor necrosis factor (2)
- tumor-associated macrophages (2)
- tyrosine kinase inhibitors (2)
- ubiquitination (2)
- urological cancer (2)
- very high risk (2)
- working memory (2)
- Ärztliche Aufklärung (2)
- (sub-) luxation (1)
- 1-propanol (1)
- 2-AG (1)
- 2-Arachidonoyl glycerol (1)
- 2-deoxy-d-glucose (1)
- 26 LncRNA (1)
- 2′,3′-cGAMP (1)
- 3-year survival (1)
- 3D gait analysis (1)
- 3D printing using composite resin (1)
- 3D printing using zirconia (1)
- 3D rapid prototyping (1)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- 8 weeks (1)
- ABCB5 (1)
- ACE inhibitor (1)
- ACLF (1)
- ADAM15 (1)
- ADCC (1)
- AGMO (1)
- AIDS (1)
- AKT (1)
- AKT signaling (1)
- ALD (1)
- ALDH2 (1)
- AML (1)
- AO-PCCF (1)
- APT-CEST (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- ATG3 (1)
- AU-rich element (1)
- Accidents (1)
- Acinetobacter baumannii (1)
- Acquired resistance (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute inflammation (1)
- Acute kidney failure (1)
- Acute kidney injury (1)
- Acute respiratory distress syndrom (1)
- Adiposity (1)
- Adults (1)
- Advanced stage (1)
- Adverse effects (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Affective Misattribution Procedure (1)
- Ag-RDT (1)
- Aganglionosis (1)
- Aging (1)
- Albumin (1)
- Algorithms (1)
- Alpha power (1)
- Alpha-fetoprotein (AFP) (1)
- Alzheimer's disease (1)
- Amblyopia (1)
- Amino acids (1)
- Amniotic fluid (1)
- Amphetamine (1)
- Analysis tool (1)
- Anandamide (1)
- Anemia management (1)
- Angiomyolipoma (1)
- Angststörungen (1)
- Animal disease models (1)
- Animal experiment (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antibody avidity (1)
- Anticonvulsant (1)
- Antimicrobial treatment (1)
- Antiretroviral therapy (1)
- Anwendbarkeit (1)
- Anxiety (1)
- Apoptotic cell death (1)
- Ara h2-specific IgE (1)
- Artificial intelligence (1)
- Asparaginase (1)
- Aspergillus (1)
- Astrocytoma (1)
- Ataxia telangiectasia (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Autism (1)
- Autism Spectrum disorder (1)
- Autism spectrum disorder (1)
- Autologous biomaterial (1)
- Ayurveda (1)
- B cells (1)
- B-cell transcription factors (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BCORL1 (1)
- BCX7353 (1)
- BEACOPP (1)
- BMI (1)
- BMNC (1)
- BNT162b2 (1)
- BNT2b2 (1)
- BPO (1)
- BPTF (1)
- BRD4 (1)
- Back scan (1)
- Bacterial leakage (1)
- Barrier (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Basal ganglia (1)
- Beckwith–Wiedemann syndrome (1)
- Behandlungspfad (1)
- Behavioural ecology (1)
- Berotralstat (1)
- Bevacizumab (1)
- Big Five (1)
- Bio safety (1)
- Biofilm (1)
- Biological profile (1)
- Biomarker (1)
- Biomarkers (1)
- Biophysical models (1)
- Biophysics (1)
- Biopsy (1)
- Birth (1)
- Birth weight (1)
- Bleeding (1)
- Blood coagulation disorder (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Blood plasma (1)
- Blood sampling (1)
- Blutungskontrolle (1)
- Body sway (1)
- Bone cement implantation syndrome (1)
- Bone diseases, Metabolic (1)
- Bone metastases (1)
- Bowel obstruction (1)
- Bradycardia (1)
- Brain metastasis (1)
- Brain tumor (1)
- Browsertool (1)
- Burkitt’s lymphoma (1)
- C-reactive protein (1)
- C1 inhibitor (1)
- CAD-CAM (1)
- CAD/ CAM crown (1)
- CAD/CAM crown (1)
- CAM (1)
- CAPON (1)
- CCC-2 (1)
- CD16 (1)
- CD34+ cell enumeration (1)
- CD36 (1)
- CD45RA Depletion (1)
- CD47 (1)
- CD62L (1)
- CD8+ T cells (1)
- CDH13 (1)
- CDK2 (1)
- CDK4/6 inhibitors (1)
- CDK9 (1)
- CEST EPI (1)
- CNDAC (1)
- COMP (1)
- COPD (1)
- COVID-19 pandemic (1)
- COVID-19 vaccination (1)
- COVID-19, Primary care (1)
- COVID‐19 (1)
- CRISPR/Cas (1)
- CRPC (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CTLA-4 (1)
- Cabozantinib (1)
- Calcium (1)
- Calcium calmodulin kinase (1)
- Calliphoridae (1)
- Cancer genomics (1)
- Cancer survivors (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Cannabis (1)
- Cardiac biomarkers (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardio-oncology (1)
- Cardiotoxicity (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular magnetic resonance (1)
- Carotid injury (1)
- Case report (1)
- Catumaxomab (1)
- Cell death (1)
- Cell division (1)
- Cell-based Assays (1)
- Cement gap (1)
- Ceramides (1)
- Checkpoint Inhibitor (1)
- Chikungunya (1)
- Chimeric Antigen Receptor (CAR) (1)
- Cholinergic (1)
- Chrna7 knockout (1)
- Circadian (1)
- Clinical Global Impression of Change (1)
- Clinical Trials and Observations (1)
- Clinical decision support systems (1)
- Clinical pathway (1)
- Clinical pharmacology (1)
- ClpB (1)
- Cochlear implantation (1)
- Cognitive dysfunction (1)
- Cohort studies (1)
- Colorectal cancer (1)
- Colorimetric blood loss estimation (1)
- Combined surgical therapy (1)
- Combustion (1)
- Complex decongestive therapy (1)
- Complicated stage (1)
- Complications (1)
- Computational models (1)
- Computational neuroscience (1)
- Computational science (1)
- Computed tomography, X-ray (1)
- Computer hardware (1)
- Computer science (1)
- Computer software (1)
- Computer-assisted diagnosis (1)
- Cone-beam computed tomography (1)
- Conometric connection (1)
- Consensus document (1)
- Constipation (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Continuous renal replacement therapy (1)
- Contrast agent (1)
- Corneal tomography (1)
- Corona virus (1)
- Coronary heart disease (1)
- Costs (1)
- Course (1)
- Covid-19 (1)
- Cre-recombinase (1)
- Crisis (1)
- Critical care (1)
- Cue-P3 (1)
- Culicidae (1)
- Custom-made mouthguard (1)
- Cyclin T1 (1)
- Cystatin C (1)
- DC-NK cell interaction (1)
- DCK (1)
- DNA integrity (1)
- DPPIV (1)
- Data Analysis (1)
- Data processing (1)
- Data reduction (1)
- Daubert criteria (1)
- Dead space (1)
- Decision support (1)
- Deep brain stimulation (1)
- Degradation (1)
- Dengue (1)
- Dentists (1)
- Developmental Biology (1)
- Dexamethasone (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diffusion magnetic resonance imaging (1)
- Diphtheria (1)
- Diptera (1)
- Direct measurement (1)
- Direct oral anticoagulation (1)
- Disease progression (1)
- Diseases (1)
- Dislocations of the knee (1)
- Dizygotic ectopic (1)
- Dopamine (1)
- Dose response (1)
- Droplets (1)
- Drospirenon (1)
- Drug addiction (1)
- Drug resistance (1)
- Drug targets (1)
- Drug therapy (1)
- Dual-energy computed tomography (1)
- Dynamic MRI (1)
- Dysfunctional social assumptions (1)
- D’Amico classification (1)
- EBRT (1)
- ECMO (1)
- EET (1)
- EHL concentrates (1)
- ENIGMA (1)
- EP300 (1)
- EQ5D5L (1)
- EQA scheme (1)
- ER-phagy (1)
- ERAL1 (1)
- ERK inhibitor (1)
- ERK1/2 signaling (1)
- ESBL (1)
- Early setting (1)
- Eccentric fixation (1)
- Ectopic pregnancy (1)
- Effective half-life (1)
- Efficacy (1)
- Efficiency (1)
- Electric stimulation (1)
- Elternurteil (1)
- Emergency room (1)
- Ena/VASP proteins (1)
- Encephalopathy (1)
- Endocrine system and metabolic diseases (1)
- Endocrine therapy (1)
- Endothelial cells (1)
- Endothelial progenitor cells (1)
- Energy (1)
- Engraftment (1)
- Enterobacterales (1)
- Environmental biotechnology (1)
- Environmental sciences (1)
- EpCAM positive tumor (1)
- Ephrin-B2–EphB4 (1)
- Epigenetics (1)
- Epileptische Anfälle (1)
- Epileptischer Anfall (1)
- Epithelialization (1)
- Epsilon (1)
- Estimated glomerular filtration rate (1)
- Event related potentials (1)
- Everolimus (1)
- Evidence-based (1)
- Evidenzbasiert (1)
- Ewing sarcoma (1)
- Ewing-like (1)
- Exercise (1)
- Exercise training (1)
- Exoscope (1)
- Exosomes (1)
- Expansion (1)
- Expectation violation (1)
- External beam radiotherapy (1)
- Extracellular matrix (1)
- Extracellular vesicles (1)
- Exudates and transudates (1)
- FABP (1)
- FAM134 (1)
- FFP3 respirator (1)
- FGFR (1)
- FOXO1 (1)
- FOXO3 (1)
- FXR (1)
- Facial nerve (1)
- Falls (1)
- Feasibility studies (1)
- Fendrr (1)
- Fertility counseling (1)
- Filariasis (1)
- Fluid overload (1)
- Fluorescence (1)
- Forensic entomology (1)
- Forensic experts (1)
- Forensic pathology (1)
- Frontobasal (1)
- Fuchs endothelial dystrophy (1)
- G2A (1)
- GD2 (1)
- GEMs (1)
- GFR (1)
- GIIb/IIIa-receptor (1)
- GMP (1)
- GPCR (1)
- GPR4 (1)
- GTP cyclohydrolase (1)
- Ganglionic (1)
- Gan–Dou–Fu–Mu decoction (GDFMD) (1)
- Gastric motility (1)
- Gastroenterology (1)
- Gender (1)
- Gene expression (1)
- General Practitioner (1)
- Genetic techniques (1)
- Genetics research (1)
- Genome editing (1)
- Gestagen-Monopräparate (1)
- Gezielte Therapie (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- Gleason grade group (1)
- Glioblastoma survival (1)
- Glomerulosclerosis (1)
- Glycolysis (1)
- Grading (1)
- Graft (1)
- Graft quality (1)
- Granulocytes (1)
- Graves’ disease (1)
- Gravimetric method (1)
- Guidance (1)
- Guide profession (1)
- Gut (1)
- H1N1 (1)
- HAE (1)
- HARS2 (1)
- HBV (1)
- HCC (1)
- HCC marker (1)
- HDR-brachytherapy (1)
- HER2 (1)
- HIV (1)
- HIV protease inhibitors (1)
- HL7 FHIR (1)
- HLA antibodies (1)
- HNSCC (1)
- HOLEP (1)
- HOTAIR (1)
- HPO (1)
- HPV-positive OPSCC (1)
- HRCT (1)
- HSC (1)
- HSP (hereditary spastic paraplegia) (1)
- HVPG (1)
- Haematologic diseases (1)
- Haemophilia (1)
- HeLa cells (1)
- Head and neck cancer (1)
- Health care workers (1)
- Health services (1)
- Health surveys (1)
- Healthcare resource utilisation (1)
- Healthcare resource utilization (1)
- Healthy adults (1)
- Healthy men (1)
- Heart (1)
- Heart transplantation (1)
- Heartrate (1)
- Hematologic adverse events (1)
- Hematopoietic stem cell (1)
- Hematotoxicity (1)
- Hepatic stellate cell (1)
- Hepatocellular carcinoma (1)
- Hepatocellular carcinoma (HCC) (1)
- Hereditary angioedema (1)
- Herniated disk (1)
- Heterotopic pregnancy (1)
- Hierarchical drift-diffusion modeling (1)
- High altitude (1)
- High-risk prostate cancer (1)
- Himalayas (1)
- Hip hemiarthroplasty (1)
- Hirschsprung disease (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- HoLEP (1)
- Hormone receptor positive breast cancer (1)
- Hydromineral (1)
- Hymenoptera venom allergy (1)
- IAP (1)
- ICG (1)
- IFN-β (1)
- IL-17A (1)
- IL-1b (1)
- IL-33 (1)
- INR (1)
- IPSS (1)
- ISR (1)
- IgA deficiency (1)
- Ileostomy (1)
- Ileus (1)
- Image processing (1)
- Immune cells (1)
- Immune checkpoint inhibitors (1)
- Immune complex vasculitis (1)
- Immune paralysis (1)
- Immune status (1)
- Immunodeficiency (1)
- Immunogenetics (1)
- Immunoglobulins (1)
- Immunohistochemistry (1)
- Immunophenotyping (1)
- Immuno‑histochemistry (1)
- Implantable cardioverter-defibrillator (1)
- Implicit Processing (1)
- Implicit Association Test (1)
- In vivo electrophysiology (1)
- Inactivation (1)
- IncX (1)
- Incidence rate (1)
- Incontinence (1)
- Indication for fertility preservation (1)
- Indirect treatment comparison (ITC) (1)
- Indocyanine green (1)
- Indonesia (1)
- Injuries (1)
- Injury (1)
- Intention attribution (1)
- Interleukin-10 (1)
- International normalized ratio (1)
- Internet-based therapy (1)
- Interpretation Bias (1)
- Intervention (1)
- Intervertebral disc displacement (1)
- Interviews (1)
- Intimal-medial thickness (1)
- Intraoperative blood salvage (1)
- Intrinsic resistance (1)
- Intubation (1)
- Isoflurane (1)
- Isothermal amplification (1)
- Ixodes ricinus (1)
- JAK2V617F (1)
- KCCQ (1)
- KCNQ1 (1)
- KLHL11 (1)
- KPS (1)
- Kallikrein inhibitor (1)
- Kappa (1)
- Keap1-Nrf2 (1)
- Ki-67 (1)
- Kindes- und Jugendalter (1)
- Knee surgery (1)
- Kontrazeption (1)
- LARS2 (1)
- LDHB (1)
- LEOSS (1)
- LPS (1)
- LQTS (1)
- LSCC (1)
- LSEC (1)
- LanCL2 (1)
- Lasers (1)
- Lateral flow antigen testing (1)
- Lateral flow immunoassay (1)
- Learning and memory (1)
- Lee type, functional outcome (1)
- Legal medicine (1)
- Leigh syndrome (1)
- Leishmaniasis (1)
- Lemperle (1)
- Leukemia (1)
- Leukocyte depletion filter (1)
- Lipedema (1)
- Liposuction (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Local therapy (1)
- Long non-coding RNA (1)
- Long non-coding RNAs (1)
- Low grade glioma (1)
- Low-molecular-weight heparin (1)
- Low-virulent infection (1)
- Lung neoplasms (1)
- Lymphocyte subpopulations (1)
- Lymphopenia Mortality (1)
- MDD (1)
- MEIS (1)
- MEK inhibitor (1)
- MLKL (1)
- MN1 (1)
- MRI-negative epilepsy (1)
- MTOR inhibitor (1)
- MTRasym (1)
- MVPA (1)
- MYC (1)
- MYCN amplification (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Major depressive disorder (1)
- Malaria (1)
- Malignant meningioma (1)
- Manchester scar scale (1)
- Marginal integrity (1)
- Masking effect (1)
- Mastoiditis (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Materials science (1)
- Mathematical functions (1)
- Maxillofacial reconstruction (1)
- Maxillofacial trauma (1)
- Medical history (1)
- Meersseman test (1)
- Meningioma (1)
- Mental health and psychiatry (1)
- Mental health therapies (1)
- Metabolic diseases (1)
- Metabolic dysfunction (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metalloproteinases (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Methanol (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Method validation (1)
- Methylphenidate (1)
- MiSpEx-network (1)
- Micro computed tomography (1)
- MicroRNAs (1)
- Microbiology and Infectious Disease (1)
- Microgap (1)
- Microwave ablation (1)
- Minimal invasive dentistry (1)
- Mitochondrial ROS (1)
- Mitochondrial dysfunction (1)
- Mitosis (1)
- Molecular Biology (1)
- Molecular diagnostics (1)
- Molecular neuroscience (1)
- Monoclonal antibody (mAb) (1)
- Monocytes (1)
- Mosquito (1)
- Motivation (1)
- Mountain (1)
- Multianalyte detection (1)
- Multidrug-resistant organisms (1)
- Multiligament instability (1)
- Multivariate analysis (1)
- Musculoskeletal abnormalities (1)
- Musculoskeletal problems (1)
- Musculoskeletal system (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myeloid Neoplasia (1)
- Myiasis (1)
- Myocardial infarction (1)
- Myocardial remodeling (1)
- N471D strumpellin knock-in mice (1)
- N501Y (1)
- NAFLD (1)
- NASH (1)
- NET (1)
- NFkB (1)
- NK cell subsets (1)
- NK-92 (1)
- NO (1)
- NOS-I (1)
- NOS1AP (1)
- NSBB (1)
- NURF (1)
- Natural killer cells (1)
- Necroptosis (1)
- Necrotizing enterocolitis (1)
- Negligence (1)
- Nephrectomy (1)
- Neural stem cells (1)
- Neurodegeneration (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Neurofilament light chain (1)
- Neuroligins (1)
- Neurooncology (1)
- Neuropilin (1)
- Neurotoxicity (1)
- Neurovascular damage (1)
- Next-generation sequencing (1)
- NfL (1)
- Niche (1)
- Nicotine (1)
- Nitric oxide (1)
- Nonaerosolizing treatment (1)
- Nontuberculous mycobacteria (1)
- Noradrenergic (1)
- Norepinephrine (1)
- Nox4 (1)
- Nrf-2 (1)
- Nrf2 (1)
- Nutrition (1)
- OA (1)
- OGR1 (1)
- OHIP-G14 (1)
- OHRQoL (1)
- ORP (1)
- OSCE (1)
- OXA-48 (1)
- OXA-484 (1)
- OXPHOS (1)
- Obstetrics and gynecology (1)
- Occlusion treatment (1)
- Occupational health (1)
- Older patient (1)
- Olfactory groove meningioma (1)
- Olfactory system (1)
- Oligodendroglioma (1)
- Oligometastatic (1)
- Omega lipids (1)
- Oncogenes (1)
- Oncology (1)
- Online Survey (1)
- Opinion (1)
- Opioids (1)
- Opportunistic infections (1)
- Oral food challenge (1)
- Oral immunotherapy (OIT) (1)
- Oral therapy (1)
- Orbital fracture (1)
- Organ failure (1)
- Organ injury (1)
- Orthodontic tooth movement (1)
- Osteoporotic fractures (1)
- Otorhinolaryngological (1)
- Outcomes (1)
- Outcomes research (1)
- Outpatients (1)
- Overweight (1)
- Oxidative phosphorylation (1)
- P2X7 receptor (1)
- PAC-1 (1)
- PAD-test (1)
- PAPR (1)
- PATZ1 (1)
- PBSC (1)
- PBX (1)
- PD-1 (1)
- PD-L1 (1)
- PLAGL1 (1)
- PMA (1)
- PML (1)
- PMMA (1)
- POCT (1)
- POR (1)
- PPAR-γ (1)
- PRF (1)
- PRNT (1)
- PRRT (1)
- PSA (1)
- PTEN inducible kinase 1 (1)
- PTM (1)
- Pacemaker (1)
- Pain (1)
- Pain management (1)
- Palacos reaction (1)
- Pandemie (1)
- Parenteral nutrition (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Particulates (1)
- Pathogens (1)
- Pathology (1)
- Pathophysiology (1)
- Patient manikins (1)
- Patient perspective (1)
- Patient preference (1)
- Patterns of care (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Pediatric surgery (1)
- Per1−/−-mice (1)
- Peri-implant disease (1)
- Peritoneal macrophages (1)
- Peritumoural oedema (1)
- Peri‑implantitis (1)
- Persistence SARS-CoV-2 antibodies (1)
- Personal protective equipment (1)
- Personalisierte translationale Therapie (1)
- Personalized medicine (1)
- Phagocytosis (1)
- Phantoms (imaging) (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Pharmacotherapy (1)
- Phase 3 (1)
- Phase 3 trial (1)
- Phenylketonuria (PKU) (1)
- Physical self-perception (1)
- Play (1)
- Pleasure (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Podospora anserina (1)
- Point of care (1)
- Point-of-care wound diagnostics (1)
- Poly-Pore (1)
- Polypharmacy (1)
- Population dynamics (1)
- Portal veins (1)
- Post mortem examination (1)
- Post-cesarean (1)
- Post-offence drinking (1)
- Post-thaw recovery (1)
- Post-traumatic stress disorder (1)
- Postmortem (1)
- Postmortem interval (1)
- Posture analysis (1)
- Potassium iodide (1)
- Powered air-purifying respirator (1)
- Pre-analytics (1)
- Preclinical research (1)
- Prediction of locoregional recurrence (1)
- Predictive coding (1)
- Predictive markers (1)
- Predictive model (1)
- Prevention (1)
- Preventive medicine (1)
- Primary care (1)
- Primary health care (1)
- Primary molars (1)
- Primärversorgung (1)
- Principal component analysis (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Proficiency testing (1)
- Prognostic markers (1)
- Prognostic models (1)
- Protease inhibitor therapy (1)
- Proximal (1)
- Pseudomonas aeruginosa (1)
- Pseudophakia (1)
- Psoriasis (1)
- Psoriatic arthritis (1)
- Psychiatric disorders (1)
- Psychiatry (1)
- Psychology (1)
- Pyogenic spondylodiscitis (1)
- Python (1)
- Qualitative study (1)
- Quality control (1)
- RARP (1)
- RAS pathway (1)
- RCT (1)
- RET (1)
- RGAG1 (1)
- RMS (1)
- RNA (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- RNA therapy (1)
- RNA-binding protein (1)
- RNA-sequencing (1)
- RNAP II (1)
- RND (1)
- RNF4 (1)
- ROC analyses (1)
- ROC-Analysen (1)
- ROS1 (1)
- RT-PCR-detection (1)
- Race (1)
- Radiation Oncology (1)
- Radiation necrosis (1)
- Radical prostatectomy (1)
- Radiochemotherapy (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Radiology (1)
- Radiomics (1)
- Radiosurgery (1)
- Ramucirumab (1)
- Randomisation (1)
- Randomized Controlled Trial (1)
- Randomized controlled trial (1)
- Reactive oxygen species (1)
- Ready-made mouthguard (1)
- Real-time MRI (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Rectal cancer (1)
- Redoxin (1)
- Refractive changes (1)
- Region (1)
- Registry (1)
- Renal cell carcinoma (1)
- Rescue medication (1)
- Resection (1)
- Residual myometrial thickness (1)
- Respiratory distress syndrome (1)
- Respiratory infections (1)
- Response control (1)
- Restenosis (1)
- Resting-state (1)
- Retrospective study (1)
- Reward (1)
- Rhabdomyoma (1)
- Rho-kinase (1)
- Ridge preservation (1)
- Riftia pachyptila (1)
- Risk factor (1)
- Risk stratification (1)
- Roussel Uclaf Causality Assess- ment Method (RUCAM) (1)
- S1P lyase (1)
- S63845 (1)
- SAH (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS-CoV-2 testing (1)
- SARS-CoV‑2 (1)
- SCCHN (1)
- SCD14 (1)
- SEC-ICP-DRC-MS (1)
- SEER (1)
- SELEX (1)
- SF-36 (1)
- SGPL1 (1)
- SGPL1 knockout cell line (1)
- SH-SY5Y neuroblastoma cells (1)
- SIRPalpha (1)
- SIRT1 (1)
- SKALE score (1)
- SLC6a3 (1)
- SLC7A11 (1)
- SPG8 (1)
- SUMO (1)
- Safety (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sandfly (1)
- Sapacitabine (1)
- Sarcoma (1)
- Satisfaction (1)
- Scheimpflug imaging (1)
- Schizophrenia (1)
- Sclerotic glomeruli (1)
- Screeningfragebogen (1)
- Seasonal variation (1)
- Sedation (1)
- Sedatives (1)
- Seizures (1)
- Self-esteem (1)
- Sequencing (1)
- Short bowel syndrome (1)
- Side effect (1)
- Silver diamine fluoride (1)
- Simulated patients (1)
- Simulation training (1)
- Single-cell RNA sequencing (1)
- Skeletal health (1)
- Skull base (1)
- Slow Cortical Potentials, SCP (1)
- Smac mimetics (1)
- Smoking habits (1)
- Social Phobia (1)
- Social cognition (1)
- Social decision-making (1)
- Social neuroscience (1)
- Sociodemographic characteristics (1)
- Socket healing (1)
- Socket preservation (1)
- Soft tissue healing (1)
- Software (1)
- Solar insolation (1)
- Sonication (1)
- Sonography (1)
- Spinal fractures (1)
- Spinal surgery (1)
- Sport (1)
- Stability (1)
- Standard value (1)
- Standardization (1)
- Static MRI (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stereotactic ablative body radiotherapy (1)
- Stimulant (1)
- Sting challenge (1)
- Structured written feedback (1)
- Subependymal giant cell astrocytoma (1)
- Sudden Cardiac Death (SCD) (1)
- Suicidality (1)
- Sunlight (1)
- Superficial vein thrombosis (1)
- Supratentorial (1)
- Surgical blood loss (1)
- Surgical site infection (1)
- Sustained attention (1)
- Symmetrical blocked occlusion (1)
- Synaptic organizer (1)
- Synaptic transmission (1)
- Synaptosomal preparation (1)
- Syndecan-1 (1)
- Synthetic biology (1)
- Syrian hamster (1)
- Systematic review (1)
- T-cell development (1)
- T-cell receptor (TCR) (1)
- T-cells (1)
- TACE (1)
- TAM (1)
- TAVI (1)
- TDAG8 (1)
- TGF-β1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TIPS (1)
- TLR4 (1)
- TME (1)
- TMT (1)
- TRAIL (1)
- TRP2 (1)
- TRPM8 (1)
- TRPV4 (1)
- TSP-4 (1)
- TTFields (1)
- TURP (1)
- TWNK (1)
- Taekwondoka (1)
- Tailored therapy (1)
- Tar (1)
- Targeted therapy (1)
- Telemedicine (1)
- Temozolomide (1)
- Tempo-parietal junction (1)
- Temporomandibular joint (1)
- Temporomandibular joint dysfunction (1)
- Tetanus (1)
- Tetrahydrobiopterin (1)
- Theft (1)
- Therapeutic anticoagulation (1)
- Thermogenesis (1)
- Thorax (1)
- Thyroid (1)
- Time of death (1)
- Time trend (1)
- Tobacco (1)
- Tomography (1)
- Tooth segmentation (1)
- Traditional Chinese Medicine (TCM) (1)
- Traditional Indian Medicine (1)
- Trajectories (1)
- Transcranial direct current stimulation (1)
- Transcription (1)
- Transcriptomics (1)
- Transdifferentiation (1)
- Transfusion (1)
- Translation (1)
- Translational research (1)
- Transplant logistics (1)
- Transplantation Centers (1)
- Travel times (1)
- Trisomy 21 (1)
- Troponin (1)
- Tuberous sclerosis complex (1)
- Tumor cell (1)
- Type three hypersensitivity (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Tyrosinemia (1)
- UTUC (1)
- Ulixertinib (1)
- Understanding (1)
- Undiagnosed patients (1)
- Upper airway infection (1)
- Upper body posture (1)
- Urethral cancer (1)
- Uterus (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGF receptors (1)
- VRE (1)
- Vaccine (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Ventilators (1)
- Video rasterstereography (1)
- Virtual noncalcium reconstructions (1)
- Virus trapping (1)
- Visual quality (1)
- WASH complex subunit 5 (1)
- WIPI2 (1)
- WIPI2b (1)
- Weight distribution (1)
- White blood cells (1)
- White matter hyperintensity (1)
- Wilson disease (WD) (1)
- Wnt (1)
- Working memory capacity (1)
- Wound healing (1)
- Wounds and injuries (1)
- X-ray computed (1)
- Yoga (1)
- Zika Virus (1)
- Zika fever (1)
- Zymosan-induced peritonitis (1)
- ablation (1)
- abscisic acid (1)
- abscopal effect (1)
- acetaminophen (1)
- acne inversa (1)
- acoustic radiation force impulse (1)
- action (1)
- activated factor XIII (1)
- acute decompensation (1)
- acute pain (1)
- acute stroke care (1)
- adaptation (1)
- adenosine (1)
- adhesion (1)
- adipocytes (1)
- adipose-derived stromal/stem cells (1)
- adjuvant chemotherapy (1)
- adolescence (1)
- adolescent (1)
- adult (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- aged (1)
- agent-based models (1)
- agility (1)
- agreeableness (1)
- air abrasive (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic stem cell transplant (1)
- allostasis (1)
- alpha power (1)
- alpha-synuclein (1)
- alpha7 nicotinic acetylcholine receptor (1)
- amide proton transfer (1)
- amyotrophic lateral sclerosis (1)
- aneurysm (1)
- animal model (1)
- anorectal malformation (1)
- anti-neural autoantibodies (1)
- antiadhesive composites (1)
- antibacterial composites (1)
- antibiotic prophylactic therapy (1)
- antibiotic prophylaxis (1)
- antibiotics (1)
- anticipation (1)
- anticoagulation (1)
- antiepileptic drug (1)
- antihelix shaping (1)
- antimicrobial stewardship (1)
- antiviral signaling (1)
- anxiety (1)
- anxiety disorders (1)
- aortic root replacement (1)
- aortic valve repair (1)
- aortic valve stenosis (1)
- aortic valve-sparing (1)
- aphrodisin (1)
- apical constriction (1)
- apical polarity (1)
- aptamer (1)
- aptamer modeling (1)
- arterial stiffness (1)
- articular cartilage (1)
- artifacts (1)
- artificial feeding (1)
- artificial intelligence (1)
- artificial intelligence (AI) (1)
- assembly (1)
- assembly factor (1)
- asthma (1)
- asymptomatic temporal encephaloceles (1)
- at-risk mental state (1)
- ataxia (1)
- atopic dermatitis (1)
- atrial fibrillation (1)
- attachment (1)
- attention (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory (1)
- auditory cortex (1)
- augmentation (1)
- autism (1)
- autoantibodies (1)
- autobiographical memories (1)
- autogenous tooth roots (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- automatic scene classification (1)
- autophagy inhibition (1)
- azacitidine (1)
- bacteremia (1)
- bacteria (1)
- bacterial leakage (1)
- bacterial viability (1)
- bacteriophages (1)
- ball (1)
- basilar artery occlusion (BAO) (1)
- bats (1)
- behavioral inhibition (1)
- behavioural rhythms (1)
- benfooxythiamine (1)
- best medical treatment (1)
- beta-band activity (1)
- beta-lactamases (1)
- bibliometric analysis (1)
- bilateral (1)
- bile (1)
- bile acids (1)
- binocular vision (1)
- biochemical relapse free survival (1)
- biologization (1)
- bladder neck stenosis (1)
- blood cell mutations (1)
- blood coagulation (1)
- blood concentrates (1)
- blood culture (1)
- blood transfusion (1)
- blood-brain barrier (1)
- bloodstream infections (1)
- body plethysmography (1)
- bone (1)
- bone augmentation (1)
- bone barrow (1)
- bone regeneration (1)
- bone-regeneration (1)
- bowel dysfunction (1)
- brachytherapy (1)
- brain disorders (1)
- brain imaging (1)
- brain infection (1)
- brain metastases (1)
- cAMP (1)
- cGMP (1)
- callous-unemotional traits (1)
- calretinin (1)
- cancer cell metabolism (1)
- cancer immunotherapy (1)
- cancer metastases (1)
- cancer specific survival (1)
- cancer surveillance (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabinoid receptors (1)
- carbapenem resistance (1)
- carbapenemases (1)
- cardiac differentiation (1)
- cardiac magnetic resonance (1)
- cardiac regeneration (1)
- cardiac reprogramming (1)
- cardiocerebral resuscitation (1)
- cardiomyocyte apoptosis (1)
- cardiomyocyte proliferation (1)
- cardiomyocytes (1)
- cardiopulmonary resuscitation (1)
- cardiovascular disease (1)
- caregivers (1)
- cartilage (1)
- castration resistance (1)
- cell barrier integrity (1)
- cell culture (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular therapies (1)
- central nervous system (1)
- central spasticity (1)
- ceramides (1)
- cerebral imaging (1)
- cerebral ischemia (1)
- cerebral metastasis (1)
- cerebral palsy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cervical cancer (1)
- cetuximab (1)
- chaperone-mediated autophagy (1)
- chemokines (1)
- chemoradiotherapy (1)
- childhood cancer (1)
- children and adolescents (1)
- cholesterol (1)
- cholinergic system (1)
- chronic (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic inflammation (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- clindamycin (1)
- clinical decision-making (1)
- clinical high at-risk mental state (1)
- clinical isolates (1)
- clinical research (1)
- clinical stage (1)
- clinical teaching (1)
- clinically important restrictions and symptoms (1)
- clonal haematopoiesis (1)
- cluster analysis (1)
- cluttering (1)
- co-infection (1)
- cochlear implant (1)
- cochlear implants (1)
- collagen (1)
- collagen membranes (1)
- collective cell migration (1)
- colorectal cancer (1)
- combined modality therapy (1)
- comorbidities (1)
- complementary medicine (1)
- complete response (1)
- complex systems (1)
- compound screen (1)
- computational knowledge-discovery (1)
- computer-assisted (1)
- concordance (1)
- conduct disorder (1)
- confinement (1)
- congenital diaphragmatic hernia (1)
- congenital disorders of autophagy (1)
- conical coupling (1)
- conometric connection (1)
- consensus (1)
- conservative dentistry (1)
- constipation (1)
- contraception (1)
- control of menstrual bleeding (1)
- convulsive seizures (1)
- coping (1)
- core expression (1)
- corona virus (1)
- coronally advanced flap (1)
- corticosteroids (1)
- cost-effective (1)
- criteria (1)
- critical-size defect (1)
- critically ill patients (1)
- cross-linking (1)
- curcumin (1)
- cyclic nucleotide analogues (1)
- cyclic nucleotide binding proteins (1)
- cycling (1)
- cyclooxygenase-2 (1)
- cytochrome P450 enzymes (1)
- cytochrome P450 reductase (1)
- cytokines (1)
- cytotoxic T lymphocyte (1)
- dance teacher (1)
- data quality (1)
- data repositories (1)
- data sharing (1)
- death rates (1)
- decompressive craniectomy (1)
- default mode network (1)
- degradation (1)
- delayed diagnosis (1)
- delivery mode (1)
- delta (1)
- dendrite morphogenesis (1)
- dendritic cells (1)
- dengue vector (1)
- dental assistant (1)
- dental education (1)
- dental implant (1)
- dental school (1)
- dental treatment concept (1)
- dentist (1)
- dentist’s chair design (1)
- depth perception (1)
- desensitization (1)
- development (1)
- diabetes complication (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diet (1)
- diffuse marrow involvement (1)
- digital medicine (1)
- digital one-piece casting (1)
- digital pressing technology (1)
- digital workflow (1)
- dihydrocannabidiol (1)
- diphtheria toxin (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- dislocation (1)
- disordered iron metabolism (1)
- dobutamine stress (1)
- docetaxel (DX) resistance (1)
- dopamine transporter (1)
- dorsal attention network (1)
- double immune checkpoint inhibition (1)
- downgrading (1)
- doxycycline (1)
- drinking (1)
- drospirenone (1)
- drug (1)
- drug–drug interactions (1)
- drug–gene interactions (1)
- drug–g–gene interactions (1)
- dual-energy (1)
- dynamic causal modeling (1)
- dynamic system (1)
- early onset (1)
- early-onset prostate cancer (1)
- echo planar imaging (1)
- edentulous (1)
- efferocytosis (1)
- efflux pump (1)
- egg sampling (1)
- elastin (1)
- electrical coupling (1)
- electroanatomical mapping (1)
- electrode design (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- electrolytic cleaning (1)
- electron transfer (1)
- element speciation (1)
- emergency care (1)
- emicizumab (1)
- endodontic curriculum (1)
- endodontic education (1)
- endodontics (1)
- endothelial dysfunction (1)
- endourology (1)
- endovascular treatment (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- enzyme activity assay (1)
- epidermal growth factor receptor (1)
- epilepsy surgery (1)
- erastin (1)
- erythropoiesis (1)
- essential thrombocythemia (ET) (1)
- ethanol (1)
- everolimus (1)
- executive functions (1)
- exercise (1)
- expert witness statement (1)
- extraskeletal (1)
- eye movements (1)
- fMLP (1)
- factor XIII (1)
- faecal microbiota transfer (1)
- fall (1)
- famotidine (1)
- fasting insulin (1)
- fat grafting (1)
- fatty acid synthesis (1)
- fecal incontinence (1)
- fecal microbiota transfer (1)
- females (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- ferric derisomaltose (1)
- ferroportin (1)
- ferroptosis (1)
- ferumoxytol (1)
- fibrinolysis (1)
- fibrosis (1)
- first-time shoulder dislocation (1)
- flow cytometry (1)
- fondaparinux (1)
- fracture strength (1)
- fracture strength equation (1)
- frontotemporal dementia (1)
- full-arch restoration (1)
- function (1)
- functional connectome acute (1)
- functional magnetic resonance imaging (1)
- functional outcome (1)
- fungal sugar (1)
- fusion (1)
- fusion kinase (1)
- gait symmetry (1)
- gargle lavage (1)
- gastrointestinal stromal tumours (1)
- gender (1)
- genetic diversity (1)
- genetic variants (1)
- genetically caused iron imbalance (1)
- genotype G (1)
- geriatrics (1)
- gingival recession therapy (1)
- glecaprevir (1)
- glioma (1)
- glioma microenvironment (1)
- global health (1)
- glucose-6-phosphate dehydrogenase (1)
- glucosylceramides (1)
- glycoproteins (1)
- gp100 (1)
- graft-vs-host disease (1)
- granule polarization (1)
- graphic 3D models (1)
- great height (1)
- grisel syndrome (1)
- growth (1)
- growth inhibition (1)
- guided bone regeneration (1)
- guideline (1)
- haNK (1)
- haemophilia (1)
- harmonization (1)
- hatching (1)
- head and neck neoplasms (1)
- health database (1)
- health information interoperability (1)
- health-relatedquality of life (1)
- healthy control (1)
- hematotoxicity (1)
- hemorrhage (1)
- herb-induced liver injury (HILI) (1)
- heterogeneity (1)
- high risk (1)
- high-altitude adaptation (1)
- high-altitude pulmonary hypertension (1)
- high-fat-diet (1)
- high-risk (1)
- high-risk neuroblastoma (1)
- hip osteoarthritis (hip OA) (1)
- hippocampus (1)
- histamine (1)
- histopathological growth pattern (1)
- homeodomain protein (1)
- homeostasis (1)
- hospital admission (1)
- host-microbe interaction (1)
- human allogeneic hematopoietic cell transplantation (1)
- human behaviour (1)
- human factors (1)
- human intestinal microbiota (1)
- human olfaction (1)
- human subjects (1)
- humans (1)
- hybrid materials (1)
- hybrid production (1)
- hydrogen peroxide (1)
- hypersensitivity (1)
- hypobaric hypoxia (1)
- hypophosphatemia (1)
- hypoxia inducible factor 1 alpha (1)
- iCBT (1)
- idiosyncratic drug-induced liver injury (DILI) (1)
- image-guided tissue acquisition (1)
- imaging genetics (1)
- imaging protocol (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune escape (1)
- immune host defense (1)
- immune infiltration (1)
- immunohistochemistry (1)
- immunological risk (1)
- impulsivity (1)
- incidence (1)
- incontinence (1)
- induction chemotherapy (1)
- induction regimen (1)
- induction therapy (1)
- inertial motion units (1)
- infection (1)
- infection control (1)
- infection precaution (1)
- infections (1)
- infectivity (1)
- inflammasome (1)
- inflammatory bowel disease (1)
- inflammatory reaction (1)
- informal care (1)
- inherited (1)
- inhibitor (1)
- inhibitory control (1)
- injury pattern (1)
- injury prevention (1)
- inosine (1)
- insurance data (1)
- integrate-and-fire (1)
- integrative medicine (1)
- integrative neuromotor training (1)
- intellectual disability (1)
- intensive care admission and mortality (1)
- interim positron emissiontomography (1)
- interleukin-22 (1)
- international transport (1)
- interstitial multicatheter brachytherapy (1)
- intestinal iron loss (1)
- intestinal manipulation (1)
- intracellular (1)
- intracerebral hemorrhage (ICH) (1)
- intracranial hemorrhage (1)
- intranasal administration (1)
- intraoperatively molded (1)
- intravenous iron (1)
- intravenous iron therapy (1)
- intrinsic and innate immune response (1)
- invasive fungal disease (1)
- inverse spacer (1)
- inverse stage migration (1)
- iron deficiency anemia (1)
- iron isomaltoside (1)
- iron-trafficking (1)
- irritable bowel syndrome (1)
- jejunoileal atresia (1)
- joint innervation (1)
- joint load (1)
- juvenile myelomonocytic leukemia (1)
- kidney transplantation (1)
- kinematic analysis (1)
- landrace pigs (1)
- language impairment (1)
- lasso regression (1)
- layer-specificity (1)
- learning and memory (1)
- left atrial appendage occlusion (1)
- legislation (1)
- leisure-time activity (1)
- lenalidomide (1)
- leptin receptor-deficient mouse (1)
- leucocytes (1)
- leukemia (1)
- leukocytes (1)
- leukodystrophy (1)
- life table (1)
- life-expectancy (1)
- lifestyle intervention (1)
- light irradiation (1)
- limitations (1)
- lipids (1)
- lipofilling (1)
- lipofuscin (1)
- live-cell imaging (1)
- live/dead staining (1)
- liver X receptor (1)
- liver damage (1)
- liver metastasis (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- local drug delivery (1)
- local preemptive analgesia (1)
- local recurrence (1)
- local treatment (1)
- location (1)
- locator (1)
- logistic models (1)
- long non-coding RNA (1)
- long term (1)
- long-term outcome (1)
- long-term success (1)
- loss of B-cell phenotype (1)
- loss-of-function (1)
- low molecular weight heparin (1)
- low risk (1)
- low-back-pain (1)
- low-carbohydrate (1)
- low-dose irradiation (1)
- low-glycaemic meal replacement (1)
- lower leg fracture (1)
- lung development (1)
- lung function (1)
- lungs (1)
- lymph node metastases (1)
- mRNA stability (1)
- mRNA1273 (1)
- mTOR (1)
- mTOR inhibitor (1)
- machine-learning (1)
- magnetoencephalography (1)
- male (1)
- malignancy (1)
- mammary carcinoma (1)
- manganese (1)
- marginal fit (1)
- marked lymph node (1)
- mass spectrometry (1)
- mathematical analysis (1)
- mathematical modeling (1)
- mechanotransduction (1)
- medical risk factors (1)
- medulloblastoma (1)
- melanoma (1)
- membrane-less organelles (1)
- membranous urethral stricture (1)
- meningioma (1)
- mental health (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- mesial temporal lobe epilepsy (1)
- meta-analysis (1)
- metabolic liver disease (1)
- metabolic rewiring (1)
- metabolism (1)
- metabolomics (1)
- metastatic renal cell carcinoma (1)
- mice (1)
- michael acceptor (1)
- microbiome (1)
- microdissection (1)
- microsurgery (1)
- microvesicles (1)
- mild cognitive impairment (1)
- minimally invasive therapy (1)
- minocycline (1)
- mitochondrial disease (1)
- mitochondrial respiration (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mold (1)
- molecular marker (1)
- molecular neuroscience (1)
- molecular surveillance (1)
- monitoring (1)
- monoacylglycerol lipase (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- monocytes (1)
- monotherapy (1)
- mood (1)
- morbidity (1)
- motor functions (1)
- motor-control-exercise (1)
- mouse (1)
- mouse models (1)
- mouse tumor model (1)
- mucormycetes (1)
- multi-material 3D printing (1)
- multi-scale models (1)
- multicenter study (1)
- multicentre study (1)
- multidisciplinary-therapy (1)
- multimorbidity (1)
- multiple myeloma (1)
- multisensory integration (1)
- multislice imaging (1)
- multivoxel pattern analysis (1)
- musculoskeletal disorders (1)
- musculoskeletal repair (1)
- musculoskeletal system (1)
- mutation (1)
- mutism (1)
- myeloproliferative neoplasms (MPN) (1)
- myocardial efficiency (1)
- myocardial fibrosis (1)
- myocardial ischaemia (1)
- myocardial power (1)
- nNOS (1)
- nasal swab (1)
- natural selection (1)
- natural sounds (1)
- necroptosis (1)
- neoadjuvant therapy (1)
- neonate (1)
- neovascularization (1)
- nephroureterectomy (1)
- neural correlates (1)
- neural oscillations (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurodevelopmental disorde (1)
- neuroendocrine tumor (1)
- neuroethology (1)
- neurogenic bowel (1)
- neuroimaging (1)
- neurological manifestations (1)
- neurology (1)
- neuropeptide (1)
- neuropeptides (1)
- neuroprotection (1)
- neurotransmitter (1)
- neutralization (1)
- neutralizing antibody (1)
- next-generation sequencing (1)
- nitric oxide (1)
- nitroalkene (1)
- nitroglycerin (1)
- nociception (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- nomogram (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-coding RNA (1)
- non-contact injuries (1)
- non-perimesencephalic (1)
- non-small cell lung cancer (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- nucleic acid amplification test (1)
- nucleic acid docking (1)
- nucleic acid lateral flow immunoassay (1)
- nucleolus (1)
- nucleoredoxin (1)
- nutrition - clinical (1)
- nymphs (1)
- obesity (1)
- observational study (1)
- olfaction (1)
- oluble epoxide hydrolase (1)
- oncogenesis (1)
- oncogenic RAS (1)
- oncological exercise therapy (1)
- online intervention (1)
- online research (1)
- online survey (1)
- open field behavior (1)
- open science (1)
- open skill exercise (1)
- operating microscope (1)
- oral health (1)
- oral health burden (1)
- oral progestins (1)
- orale Gestagene (1)
- ordinary differential equations (ODE) (1)
- organ preservation (1)
- organic nitrates (1)
- organotypic culture (1)
- other cause mortality (1)
- otoplasty (1)
- outcomes (1)
- ovarian cancer (1)
- overdenture (1)
- overtreatment (1)
- overweight (1)
- oviposition (1)
- oviposition substrate (1)
- ovitrap (1)
- oxaliplatin (1)
- oxythiamine (1)
- p-eIF2α (1)
- p21Cip1/CDKN1A (1)
- p53 pathway (1)
- pH (1)
- pad-test (1)
- pain intensity (1)
- paired samples (1)
- palliative care (1)
- palliative care services (1)
- pancreatic ductal adenocarcinoma (1)
- pannexin-1 (1)
- paper-based detection (1)
- paracrine signaling (1)
- parent rating (1)
- pathogen (1)
- patient preferences (1)
- patient safety (1)
- patient–doctor relationship (1)
- pediatric solid tumors (1)
- pelvic trauma (1)
- penile cancer (1)
- pentaerythritol tetranitrate (1)
- peptide receptor radionuclide therapy (1)
- perforant path transection (1)
- peri-implant disease (1)
- peri-implant diseases (1)
- peri-implantitis (1)
- peri-implantitis treatment (1)
- periimplantitis (1)
- perimesencephalic (1)
- periodontal diseases (1)
- periodontal treatment (1)
- peripheral blood stem cell collection (1)
- peritoneal macrophages (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peroxisome proliferator-activated receptor (1)
- persistent periodontal pockets (1)
- personalized (1)
- phagocytes (1)
- phagocytosis (1)
- pharmacodynamics (1)
- pharmacoepigenetics (1)
- pharmacogenetics (1)
- pharmacological data science (1)
- pharmacological plasticity (1)
- phase IV (1)
- phase separation (1)
- phenoconversion (1)
- pheromone (1)
- phosphoproteomics (1)
- photodynamic therapy (1)
- physical activity (1)
- physiotherapy (1)
- pibrentasvir (1)
- pitch (1)
- plasmid (1)
- platelet hyperactivity (1)
- platelet substitution (1)
- platelet-rich-fibrin (1)
- point-of-care diagnostics (1)
- polo-like kinases (1)
- polyQ (1)
- polycythemia vera (PV) (1)
- polymer infiltrated ceramic network (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- polypharmacy (1)
- polytrauma (1)
- polyunsaturated fatty acid (1)
- portal pressure (1)
- positron-emissions-tomography (1)
- post-transcriptional regulation (1)
- posterior circulation (1)
- postinfectious bronchiolitis obliterans (1)
- postoperative pain (1)
- potassium channel (1)
- preclinical (1)
- prediabetes and type 2 diabetes (1)
- prediction (1)
- predictive (1)
- predictive coding (1)
- predictor (1)
- preeclampsia (1)
- prehabilitation (1)
- prepontine (1)
- preventive strategies (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- primary myelofibrosis (PMF) (1)
- prion-like (1)
- production (1)
- progestin mono-preparation (1)
- prognostic (1)
- prognostic scores (1)
- progranulin (1)
- promyelocytic leukemia nuclear bodies (1)
- prostate cancer (PCa) (1)
- prostate neoplasm (1)
- proteasome (1)
- protein aggregation (1)
- protein complexes (1)
- protein evolution (1)
- protein folding (1)
- protein phosphorylation (1)
- protein-rich (1)
- protein–protein interaction (1)
- proteoglycan (1)
- proteomics (1)
- proton pumping (1)
- proton-sensing GPCR (1)
- protruding ear (1)
- pseudomonas aeruginosa (1)
- psoriasis (1)
- psychiatric comorbidity (1)
- psychiatric disorders (1)
- psychogenic non-epileptic seizures (1)
- psychosocial factors (1)
- public health (1)
- publication output (1)
- pulsed SILAC (1)
- quantitative MRI (1)
- quantitative RUCAM (1)
- quantitative magnetic resonance imaging (1)
- quiescence (1)
- radiation (1)
- radiation-induced (1)
- radio sensitivity (1)
- radioimmunotherapy (1)
- radiomics (1)
- randomized (1)
- randomized controlled trial (1)
- rare disease (1)
- rare mendelian disorders (1)
- rat calvaria defect (1)
- re-irradiation (1)
- reactive coordination (1)
- reactive oxygen species (1)
- real-world (1)
- recall (1)
- recombinase polymerase amplification (1)
- recovery (1)
- recurrent urinary tract infections (1)
- red cells (1)
- reduced kidney function (1)
- reduction potential (1)
- regenerative therapy (1)
- relapsing–remitting multiple sclerosis (1)
- remodeling (1)
- renal cell carcinoma (1)
- renal dysfunction (1)
- renal failure (1)
- renal tubular epithelial cells (1)
- research database (1)
- research funding (1)
- resectability (1)
- resin nano ceramics (1)
- resistance (1)
- resistance mutation (1)
- resolution (1)
- response (1)
- response inhibition (1)
- resting-state (1)
- reticulocyte hemoglobin equivalent (1)
- retrospective studies (1)
- reverberation (1)
- revision knee arthroplasty (1)
- reward (1)
- reward probabilities (1)
- rheumatoid arthritis (1)
- rifampicin (1)
- risk group (1)
- risk stratification (1)
- room simulation (1)
- safety attitudes questionnaire (1)
- salience network (1)
- saliva (1)
- salvage mastectomy (1)
- salvage radical prostatectomy (1)
- sampling (1)
- sarcoma (1)
- scar (1)
- schizophrenia (1)
- screening questionnaire (1)
- searchlight analysis (1)
- second line therapy (1)
- second-line immunotherapy (1)
- second-line treatment / 2L treatment (1)
- secondary data analysis (1)
- secondary progressive multiple sclerosis (1)
- secreted Ly-6/uPAR-related protein 1 (1)
- seed and soil (1)
- segmental ureteral resection (1)
- self-collected samples (1)
- semiquinone (1)
- sensory loss (1)
- sensory organ development (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured patient (1)
- sex (1)
- sex differences (1)
- sexual arousal (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- shared decision-making (1)
- shear stress (1)
- shikonin (SHI) (1)
- short bowel (1)
- short linear motif (1)
- short-term (1)
- shoulder instability (1)
- shoulder stabilization (1)
- simulation (1)
- simulation training (1)
- sleep deprivation (1)
- sleep disordered breathing (1)
- small bowel (1)
- small ubiquitin-related modifier (1)
- social anxiety (1)
- social communication (1)
- socio-economic influences (1)
- socioeconomic factors (1)
- soft tissue (1)
- soft tissue sarcoma (1)
- solid tumor (1)
- sonoSens (1)
- sorafenib (1)
- sound-induced flash illusion (1)
- spared nerve injury (1)
- speech perception (1)
- sphingolipids (1)
- sphingosine-1-phosphate (1)
- spike mutation (1)
- spike protein (1)
- spina bifida (1)
- spinal bone metastasis (1)
- spinal infection (1)
- spine injury (1)
- spinocerebellar ataxia (1)
- splicing (1)
- split-mouth (1)
- sprouting (1)
- sprouting angiogenesis (1)
- stage (1)
- stage migration (1)
- statin (1)
- statin treatment (1)
- statins (1)
- stoma (1)
- structure-function (1)
- strumpellin (1)
- stuttering (1)
- subarachnoid hemorrhage (1)
- subchondral bone (1)
- subgrouping (1)
- subpopulation (1)
- sulforaphane (1)
- sulfur-oxidizing symbiont (1)
- superparamagnetic iron oxide nanoparticles (1)
- support (1)
- suprachiasmatic nucleus (1)
- surgical complications (1)
- surrogate ELISA (1)
- symbiosis (1)
- symptoms (1)
- synoviocytes (1)
- synovitis (1)
- systematic review (1)
- tDCS (1)
- tVNS (1)
- tachycardia (1)
- target (1)
- targeted axillary dissection (1)
- targeted sequencing (1)
- taste buds (1)
- temporal encephaloceles (1)
- temporal lobe epilepsy (1)
- testosterone (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- therapy (1)
- therapy response (1)
- thermal ablation (1)
- thrombectomy (1)
- thromboembolism (1)
- thymic selection (1)
- tibial fracture (1)
- tip cell filopodia formation (1)
- tissue reconstruction (1)
- toddler’s fracture (1)
- tolerability (1)
- topical administration (1)
- topographical pattern (1)
- torticollis (1)
- total hip replacement (1)
- toxic milk mice (TX mice) (1)
- toxicity (1)
- traditional Chinese medicine (TCM) (1)
- trafficking (1)
- training (1)
- transduction (1)
- transfer entropy (1)
- transglutaminase (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- translational investigation (1)
- translational study (1)
- transmission (1)
- transovarial transmission (1)
- transplant-free survival (1)
- transstadial transmission (1)
- trauma (1)
- traumatic brain injury (1)
- traumatic injury (1)
- treatment outcome (1)
- treatment resistance (1)
- treatment response (1)
- trials registry (1)
- triplex (1)
- trophoblast organoids (1)
- trophoblasts (1)
- trough levels (1)
- tumor immunity (1)
- tumor immunology (1)
- tumor stroma (1)
- tumor-associated macrophages (TAM) (1)
- tunnel technique (1)
- type 2 diabetes (1)
- tyrosine hydroxylase (1)
- tyrosine kinase inhibitor (TKI) (1)
- ubiquitin ligase (1)
- ultra-high risk for psychosis (1)
- unacceptable antigen mismatches (1)
- undifferentiated pleomorphic sarcoma (1)
- unilateral (1)
- unilateral hip osteoarthritis (1)
- upgrading (1)
- upper tract urothelial carcinoma (1)
- ureteroscopy (1)
- urethal stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- ursodeoxycholic acid (1)
- uveal melanoma (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- vaginal breech (1)
- vaginal hysterectomy (1)
- variants of concern (1)
- vascular biology (1)
- vasodilation (1)
- vector (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- ventral striatum (1)
- ventricular tachycardia (1)
- vergence (1)
- vertigo (1)
- very high-risk (1)
- vestibular function (1)
- viral fitness (1)
- virus (1)
- viruses (1)
- volumetric measurement technology (1)
- von Willebrand disease (1)
- waiting time (1)
- walking (1)
- wearable sensors (1)
- weight reduction (1)
- white matter hyperintensity (1)
- whole-genome sequencing (1)
- work place evaluation (1)
- wound exudate (1)
- wound healing (1)
- wound infection (1)
- wound repair (1)
- yellow flags (1)
- younger (1)
- zinc protoporphyrin (1)
- Übergewicht (1)
- ß-amyloid (1)
- β-HCG (1)
Institute
- Medizin (667)
- Biochemie, Chemie und Pharmazie (8)
- Biowissenschaften (7)
- Psychologie und Sportwissenschaften (6)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (5)
- Georg-Speyer-Haus (4)
- Physik (3)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Ernst Strüngmann Institut (2)
- Erziehungswissenschaften (2)
Introduction: Cesarean section (CS) rates are increasing worldwide. One constant indication is the breech presentation at term. By offering external cephalic version (ECV) and vaginal breech delivery CS rates can be further reduced. Objective: This study aimed to analyze the ECV at 38 weeks of gestation with the associate uptake rate, predicting factors, success rate, and complications at a tertiary healthcare provider in Germany specializing in vaginal breech delivery. Methods: We conducted a prospective cohort study with retrospective data acquisition. All women with a singleton fetus in breech presentation presenting after 34 weeks of gestation for counseling between 2013 and 2017 were included. ECV impact factors were analyzed using logistic regression. Results: A total of 1,598 women presented for breech birth planning. ECV was performed on 353 patients. The overall success rate was 22.4%. A later week of gestation (odds ratio [OR] 1.69), an abundant amniotic fluid index (AFI score) (OR 5.74), fundal (OR 3.78) and anterior (OR 0.39) placental location, and an oblique lie (OR 9.08) were significantly associated with successful ECV in our population. No major complications were observed. The overall vaginal delivery rates could be increased to approximately 14% with ECV. Conclusion: The demand for alternative birth modes other than CS for breech birth is high in the area of Frankfurt, Germany. Our study offers evidence of the safety of ECV at 38 weeks. Centers with expertise in vaginal breech delivery and ECV can reduce CS-rates. To further establish vaginal breech delivery and ECV as alternate options, the required knowledge and skill should be implemented in the revised curricula.
Background: Pathogenesis of portal hypertension is multifactorial and includes pathologic intrahepatic angiogenesis, whereby TIPS insertion is an effective therapy of portal hypertension associated complications. While angiogenin is a potent contributor to angiogenesis in general, little is known about its impact on TIPS function over time. Methods: In a total of 118 samples from 47 patients, angiogenin concentrations were measured in portal and inferior caval vein plasma at TIPS insertion (each blood compartment n = 23) or angiographic intervention after TIPS (each blood compartment n = 36) and its relationship with patient outcome was investigated. Results: Angiogenin levels in the inferior caval vein were significantly higher compared to the portal vein (P = 0.048). Ten to 14 days after TIPS, inferior caval vein angiogenin level correlated inversely with the portal systemic pressure gradient (P<0.001), measured invasively during control angiography. Moreover, patients with TIPS revision during this angiography, showed significantly lower angiogenin level in the inferior caval vein compared to patients without TIPS dysfunction (P = 0.01). Conclusion: In cirrhosis patients with complications of severe portal hypertension, circulating levels of angiogenin are derived from the injured liver. Moreover, angiogenin levels in the inferior caval vein after TIPS may predict TIPS dysfunction.
Introduction: Clinically complex patients often require multiple medications. Polypharmacy is associated with inappropriate prescriptions, which may lead to negative outcomes. Few effective tools are available to help physicians optimise patient medication. This study assesses whether an electronic medication management support system (eMMa) reduces hospitalisation and mortality and improves prescription quality/safety in patients with polypharmacy. Methods and analysis: Planned design: pragmatic, parallel cluster-randomised controlled trial; general practices as randomisation unit; patients as analysis unit. As practice recruitment was poor, we included additional data to our primary endpoint analysis for practices and quarters from October 2017 to March 2021. Since randomisation was performed in waves, final study design corresponds to a stepped-wedge design with open cohort and step-length of one quarter. Scope: general practices, Westphalia-Lippe (Germany), caring for BARMER health fund-covered patients. Population: patients (≥18 years) with polypharmacy (≥5 prescriptions). Sample size: initially, 32 patients from each of 539 practices were required for each study arm (17 200 patients/arm), but only 688 practices were randomised after 2 years of recruitment. Design change ensures that 80% power is nonetheless achieved. Intervention: complex intervention eMMa. Follow-up: at least five quarters/cluster (practice). recruitment: practices recruited/randomised at different times; after follow-up, control group practices may access eMMa. Outcomes: primary endpoint is all-cause mortality and hospitalisation; secondary endpoints are number of potentially inappropriate medications, cause-specific hospitalisation preceded by high-risk prescribing and medication underuse. Statistical analysis: primary and secondary outcomes are measured quarterly at patient level. A generalised linear mixed-effect model and repeated patient measurements are used to consider patient clusters within practices. Time and intervention group are considered fixed factors; variation between practices and patients is fitted as random effects. Intention-to-treat principle is used to analyse primary and key secondary endpoints.
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
(2021)
Background: Therapies based on targeting immune checkpoints have revolutionized the treatment of metastatic melanoma in recent years. Still, biomarkers predicting long-term therapy responses are lacking. Methods: A novel approach of reference-free deconvolution of large-scale DNA methylation data enabled us to develop a machine learning classifier based on CpG sites, specific for latent methylation components (LMC), that allowed for patient allocation to prognostic clusters. DNA methylation data were processed using reference-free analyses (MeDeCom) and reference-based computational tumor deconvolution (MethylCIBERSORT, LUMP). Results: We provide evidence that DNA methylation signatures of tumor tissue from cutaneous metastases are predictive for therapy response to immune checkpoint inhibition in patients with stage IV metastatic melanoma. Conclusions: These results demonstrate that LMC-based segregation of large-scale DNA methylation data is a promising tool for classifier development and treatment response estimation in cancer patients under targeted immunotherapy.
Background: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. Methods: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For network meta-analyses we required comparison adjusted funnel plots. We excluded treatment studies with waiting-list or treatment as usual controls. From this literature, we extracted evidence-based assertions about the disorder. Results: We generated 208 empirically supported statements about ADHD. The status of the included statements as empirically supported is approved by 80 authors from 27 countries and 6 continents. The contents of the manuscript are endorsed by 366 people who have read this document and agree with its contents. Conclusions: Many findings in ADHD are supported by meta-analysis. These allow for firm statements about the nature, course, outcome causes, and treatments for disorders that are useful for reducing misconceptions and stigma.
Background: Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention. Methods: and analysis Here we present the rationale and design of a phase 3b, randomised, double-blind, multicentre study (GUIDE), comparing treatment effects of guselkumab in patients with short (≤2 years) or longer (>2 years) duration of plaque-type psoriasis, measured from first appearance of psoriatic plaques. Participants achieving skin clearance (Psoriasis Area and Severity Index (PASI)=0) by week 20 and maintaining complete clearance at week 28 visit (‘super-responders’ (SRe)) will be randomised to continue approved maintenance dosing every 8 weeks (q8w) versus an investigational maintenance dosing interval of 16 weeks (q16w) until week 68. Primary endpoint: proportion of participants in the q8w vs q16w arms with absolute PASI <3 at week 68. Participants with PASI <3 at week 68 will be withdrawn from guselkumab treatment for up to 48 weeks. Participants not achieving SRe criteria (non-SRe) will remain in the study with q8w guselkumab dosing through week 68. Additional to serum samples obtained from all patients, skin biopsies and whole-blood samples will be taken from SRe and non-SRe participants at various time points in optional substudies. Analyses include: genetics; immunophenotyping (fluorescence-activated cell sorting); gene and protein expression profiling; immunohistology. By merging clinical endpoints with mechanistic findings, this study aims to elucidate how IL-23 blockade with guselkumab can modify the disease course by altering molecular and cellular drivers that cause relapse after treatment withdrawal, particularly among SRe. Ethics and dissemination: Approval obtained from ethics committee Medical Council Hamburg, Germany (PVN5925). GUIDE is compliant with the Declaration of Helsinki. Trial registration number: Registered at ClinicalTrials.gov (NCT03818035). All primary endpoint results (prespecified analyses) will be submitted to peer-reviewed, international journals within 18 months after primary completion date.
Circulating P2X7 receptor signaling components as diagnostic biomarkers for temporal lobe epilepsy
(2021)
Circulating molecules have potential as biomarkers to support the diagnosis of epilepsy and to assist with differential diagnosis, for example, in conditions resembling epilepsy, such as in psychogenic non-epileptic seizures (PNES). The P2X7 receptor (P2X7R) is an important regulator of inflammation and mounting evidence supports its activation in the brain during epilepsy. Whether the P2X7R or P2X7R-dependent signaling molecules can be used as biomarkers of epilepsy has not been reported. P2X7R levels were analyzed by quantitative ELISA using plasma samples from controls and patients with temporal lobe epilepsy (TLE) or PNES. Moreover, blood cell P2X7R expression and P2X7R-dependent cytokine signature was measured following status epilepticus in P2X7R-EGFP reporter, wildtype, and P2X7R-knockout mice. P2X7R plasma levels were higher in TLE patients when compared with controls and patients with PNES. Plasma levels of the broad inflammatory marker protein C-Reactive protein (CRP) were similar between the three groups. Using P2X7R-EGFP reporter mice, we identified monocytes as the main blood cell type expressing P2X7R after experimentally evoked seizures. Finally, cytokine array analysis in P2X7R-deficient mice identified KC/GRO as a potential P2X7R-dependent plasma biomarker following status epilepticus and during epilepsy. Our data suggest that P2X7R signaling components may be a promising subclass of circulating biomarkers to support the diagnosis of epilepsy.
Objective: The NADPH oxidase Nox4 is an important source of H2O2. Nox4-derived H2O2 limits vascular inflammation and promotes smooth muscle differentiation. On this basis, the role of Nox4 for restenosis development was determined in the mouse carotid artery injury model. Methods and results: Genetic deletion of Nox4 by a tamoxifen-activated Cre-Lox-system did not impact on neointima formation in the carotid artery wire injury model. To understand this unexpected finding, time-resolved single-cell RNA-sequencing (scRNAseq) from injured carotid arteries of control mice and massive-analysis-of-cDNA-ends (MACE)-RNAseq from the neointima harvested by laser capture microdissection of control and Nox4 knockout mice was performed. This revealed that resting smooth muscle cells (SMCs) and fibroblasts exhibit high Nox4 expression, but that the proliferating de-differentiated SMCs, which give rise to the neointima, have low Nox4 expression. In line with this, the first weeks after injury, gene expression was unchanged between the carotid artery neointimas of control and Nox4 knockout mice. Conclusion: Upon vascular injury, Nox4 expression is transiently lost in the cells which comprise the neointima. NADPH oxidase 4 therefore does not interfere with restenosis development after wire-induced vascular injury.
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-risk group solely by the presence of MYCN oncogene amplification (MNA). Methods: Clinical characteristics, genomic information, and outcome of 190 patients solely assigned to high-risk neuroblastoma by MNA were analyzed and compared to 205 patients with stage 4 neuroblastoma aged ≥18 months with MNA (control group). Results: Event-free survival (EFS) and overall survival (OS) at 10 years were 47% (95%-CI 39–54%) and 56% (95%-CI 49–63%), respectively, which was significantly better than EFS and OS of the control group (EFS 25%, 95%-CI 18–31%, p < 0.001; OS 32% 95%-CI 25–39%, p < 0.001). The presence of RAS-/p53-pathway gene alterations was associated with impaired 10-year EFS and OS (19% vs. 55%, and 19% vs. 67%, respectively; both p < 0.001). In time-dependent multivariable analyses, alterations of RAS-/p53-pathway genes and the extent of the best primary tumor resection were the only independent prognostic variables for OS (p < 0.001 and p = 0.011, respectively). Conclusions: Neuroblastoma patients attributed to high risk solely by MYCN amplification have generally a more favorable outcome. Mutations of genes of the RAS and/or p53 pathways and incomplete resection are the main risk factors predicting poor outcome.
Background: Bipolar disorder is associated with circadian disruption and a high risk of suicidal behavior. In a previous exploratory study of patients with bipolar I disorder, we found that a history of suicide attempts was associated with differences between winter and summer levels of solar insolation. The purpose of this study was to confirm this finding using international data from 42% more collection sites and 25% more countries. Methods: Data analyzed were from 71 prior and new collection sites in 40 countries at a wide range of latitudes. The analysis included 4876 patients with bipolar I disorder, 45% more data than previously analyzed. Of the patients, 1496 (30.7%) had a history of suicide attempt. Solar insolation data, the amount of the sun’s electromagnetic energy striking the surface of the earth, was obtained for each onset location (479 locations in 64 countries). Results: This analysis confirmed the results of the exploratory study with the same best model and slightly better statistical significance. There was a significant inverse association between a history of suicide attempts and the ratio of mean winter insolation to mean summer insolation (mean winter insolation/mean summer insolation). This ratio is largest near the equator which has little change in solar insolation over the year, and smallest near the poles where the winter insolation is very small compared to the summer insolation. Other variables in the model associated with an increased risk of suicide attempts were a history of alcohol or substance abuse, female gender, and younger birth cohort. The winter/summer insolation ratio was also replaced with the ratio of minimum mean monthly insolation to the maximum mean monthly insolation to accommodate insolation patterns in the tropics, and nearly identical results were found. All estimated coefficients were significant at p < 0.01. Conclusion: A large change in solar insolation, both between winter and summer and between the minimum and maximum monthly values, may increase the risk of suicide attempts in bipolar I disorder. With frequent circadian rhythm dysfunction and suicidal behavior in bipolar disorder, greater understanding of the optimal roles of daylight and electric lighting in circadian entrainment is needed.
Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM), and ferumoxytol (FER), are successful treatments for iron deficiency (Europe; FDI and FCM) and iron deficiency anemia (US; FDI, FCM, and FER). Areas covered: This review focusses on the chemistry and structure of FDI, FCM, and FER, and on three key aspects of IV iron safety: (1) hypersensitivity; (2) hypophosphatemia and sequelae; (3) cardiovascular safety. Expert opinion: Although the safety of modern IV iron has improved, immediate infusion reactions and the development of hypophosphatemia must be appreciated and recognized by those who prescribe and administer IV iron. Immediate infusion reactions can occur with any IV iron and are usually mild; severe reactions – particularly anaphylaxis – are extremely rare. The recognition and appropriate management of infusion reactions is an important consideration to the successful administration of IV iron. Severe, persistent, hypophosphatemia is a specific side effect of FCM. No cardiovascular safety signal has been identified for IV iron. Ongoing trials in heart failure will provide additional long-term efficacy and safety data.
Background: The aim of this study was to evaluate the longer-term results of bicuspid aortic valve (BAV) repair with or without aortic root replacement. Methods: From 1999 to 2017, 142 patients with or without aortic root dilatation who underwent repair of a regurgitant BAV were included in the study. Ninety-four patients underwent isolated BAV repair (Group 1; median age 43 years) and 48 patients underwent valve-sparing aortic root replacement plus BAV repair (aortic valve reimplantation—Group 2; median age 48 years). Median clinical follow-up time was 5.9 years (range 0.5–15) in Group 1 and 3 years (range 0.5–16) in Group 2, respectively. Results: In-hospital mortality was 1% in Group 1, and 2% in Group 2 (p = .6). The 5- and 10-year survival was 93 ± 2.9% and 81 ± 5.8% in Group 1 and 96 ± 3.1% and 96 ± 3.1% in Group 2, respectively (p = .31). Eleven patients of Group 1 (1.7%/patient-year) and five patients of Group 2 (2.2%/patient-year) underwent reoperation of the aortic valve (p = .5). The 5- and 10-year freedom from reoperation were 93.0 ± 2.1% and 77.1 ± 7.1% in Group 1 and 93.0 ± 5.0% and 76.7 ± 9.6% in Group 2 (p = .83), respectively. At the latest follow-up, only two patients of Group 1 and 1 patient of Group 2 had AV regurgitation = 2° (p = .7). The cumulative linearized incidence of all valve-related complications (bleeding, stroke, endocarditis, and reoperation) was 2.9%/patient-year in Group 1% and 4%/patient-year in Group 2, respectively (p = .6). Conclusions: Isolated BAV repair and combined aortic valve reimplantation plus BAV repair provide good clinical longer-term outcomes with relatively low reoperation rate and durable valve function.
Objective: Evaluation of survival of teeth with class III furcation involvement (FI) ≥5 years after active periodontal treatment (APT) and identification of prognostic factors. Methods: All charts of patients who completed APT at the Department of Periodontology of Goethe-University Frankfurt, Germany, beginning October 2004 were screened for teeth with class III FI. APT had to be accomplished for ≥5 years. Charts were analysed for data of class III FI teeth at baseline (T0), at accomplishment of APT (T1), and at the last supportive periodontal care (T2). Baseline radiographic bone loss (RBL) and treatment were assessed. Results: One-hundred and sixty patients (age: 54.4 ± 9.8 years; 82 females; 39 active smokers; 9 diabetics, 85 stage III, 75 stage IV, 59 grade B, 101 grade C) presented 265 teeth with class III FI. Ninety-eight teeth (37%) were lost during 110, 78/137 (median, lower/upper quartile) months. Logistic mixed-model regression and mixed Cox proportional hazard model associated adjunctive systemic antibiotics with fewer tooth loss (26% vs. 42%; p = .019/.004) and RBL (p = .014/.024) and mean probing pocket depth (PPD) at T1 (p < .001) with more tooth loss. Conclusions: Subgingival instrumentation with adjunctive systemic antibiotics favours retention of class III furcation-involved teeth. Baseline RBL and PPD at T1 deteriorate long-term prognosis.
Objective: This study was undertaken to evaluate the long-term efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. Methods: A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021. Results: Long-term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost-to-follow-up), including 10.9% reported as seizure-free. The retention rate for the entire study period was 50.8%, and at last follow-up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short-term responses, but no investigated parameters correlated with positive long-term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons. Significance: BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short-term response and retention predictors, we could not identify significant predictors for long-term outcomes. Key Points Long-term postmarketing data for brivaracetam in 262 patients showed an overall retention rate of 50.8%; At 12 months, the 50% responder rate for brivaracetam was 33.1%, with 10.9% reporting seizure freedom; Previous treatment with levetiracetam (90%) did not impact brivaracetam retention or efficacy; Levetiracetam treatment failure should not preclude brivaracetam introduction; No long-term efficacy predictors could be identified.
Musculoskeletal disorders of the trunk and neck are common among cleaners. Vacuum cleaning is a demanding activity. The aim of this study was to present the movement profile of the trunk and neck during habitual vacuuming. The data were collected from 31 subjects (21f./10 m) using a 3D motion analysis system (Xsens). 10 cycles were analysed in vacuuming PVC and carpet floors with 8 vacuum cleaners. The joint angles and velocities were represented statistically descriptive. When vacuuming, the trunk is held in a forwardly inclined position by a flexion in the hip and rotated from this position. In the joint angles and velocities of the spine, the rotation proved to be dominant. A relatively large amount of movement took place in the cervical spine and also in the lumbar spine. The shown movement profile is rather a comfort area of vacuuming which may serve as a reference for ergonomics in vacuuming.
Purpose: To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes. Methods: Within the Surveillance, Epidemiology and End Results database (2004–2016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan–Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients. Results: Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (p > 0.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (p = 0.9) for localized, 33 vs. 37% (p = 0.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (p = 0.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed. Conclusion: Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.
Purpose: In patients with pyogenic spondylodiscitis, surgery is considered the treatment of choice to conduct proper debridement, stabilise the spine and avoid extended bed rest, which in turn is a risk factor for complications such as deep vein thrombosis and pulmonary embolism. Methods: We conducted a retrospective clinical study with analysis of a group of 99 patients who had undergone treatment for pyogenic discitis at our institution between June 2012 and August 2017. Included parameters were age, sex, disease pattern, the presence of deep vein thrombosis, resuscitation, in-hospital mortality, present anticoagulation, preexisting comorbidities, tobacco abuse, body mass index, microbiological germ detection and laboratory results. Results: Among the analysed cohort, 12% of the treated patients for pyogenic spondylodiscitis suffered from a radiologically confirmed pulmonary embolism. Coronary heart disease (p < 0.01), female sex (p < 0.01), anticoagulation at admission (p < 0.01) and non-O blood type (p < 0.001) were associated with development of pulmonary embolism. Pulmonary embolism was significantly associated with resuscitation (p < 0.005) and deep vein thrombosis (p < 0.001). Neurosurgery was not associated with increased risk for pulmonary embolism compared to conservative-treated patients (p > 0.05). Conclusion: Surgery for pyogenic spondylodiscitis was not associated with an elevated risk of pulmonary embolism in our analysis. However, we describe several risk factors for pulmonary embolism in this vulnerable cohort. Prospective studies are necessary to improve prevention and postoperative management in patients with pyogenic spondylodiscitis.
HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders
(2021)
Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and reliable biomarkers allowing patients stratification are still needed. A GWAS performed by the International Consortium on Lithium Genetics (ConLiGen) has recently identified genetic markers associated with treatment responses to Li in the human leukocyte antigens (HLA) region. To better understand the molecular mechanisms underlying this association, we have genetically imputed the classical alleles of the HLA region in the European patients of the ConLiGen cohort. We found our best signal for amino-acid variants belonging to the HLA-DRB1*11:01 classical allele, associated with a better response to Li (p < 1 × 10−3; FDR < 0.09 in the recessive model). Alanine or Leucine at position 74 of the HLA-DRB1 heavy chain was associated with a good response while Arginine or Glutamic acid with a poor response. As these variants have been implicated in common inflammatory/autoimmune processes, our findings strongly suggest that HLA-mediated low inflammatory background may contribute to the efficient response to Li in BD patients, while an inflammatory status overriding Li anti-inflammatory properties would favor a weak response.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.
Background: Cases of immune complex vasculitis have been reported following COVID-19 infections; so far none in association with novel mRNA-based COVID-19 vaccination. This case report describes a cutaneous immune complex vasculitis after vaccination with BNT162b2. Case presentation: A 76-year old male with liver cirrhosis developed an immune complex vasculitis 12 days after the second injection of BNT162b2. On physical examination, the patient presented with pruritic purpuric macules on hands and feet, flexor and extensor parts of both legs and thighs and lower abdomen, and bloody diarrhoea. Laboratory testing showed elevated inflammatory markers. After short treatment with oral steroids all clinical manifestations and laboratory findings resolved. Conclusions: An increasing number of clinical manifestations have been attributed to COVID-19 infection and vaccination. This is the first written report of immune complex vasculitis after vaccination with BNT162b2. We present our case report and a discussion in the light of type three hypersensitivity reaction.
Rationale: Both attention deficit-/hyperactivity disorder (ADHD) and alcohol use disorder (AUD) are accompanied by deficits in response inhibition. Furthermore, the prevalence of comorbidity of ADHD and AUD is high. However, there is a lack of research on whether the same neuronal subprocesses of inhibition (i.e., interference inhibition, action withholding and action cancellation) exhibit deficits in both psychiatric disorders. Methods: We examined these three neural subprocesses of response inhibition in patient groups and healthy controls: non-medicated individuals with ADHD (ADHD; N = 16), recently detoxified and abstinent individuals with alcohol use disorder (AUD; N = 15), and healthy controls (HC; N = 15). A hybrid response inhibition task covering interference inhibition, action withholding, and action cancellation was applied using a 3T functional magnetic resonance imaging (fMRI). Results: Individuals with ADHD showed an overall stronger hypoactivation in attention related brain areas compared to AUD or HC during action withholding. Further, this hypoactivation was more accentuated during action cancellation. Individuals with AUD recruited a broader network, including the striatum, compared to HC during action withholding. During action cancellation, however, they showed hypoactivation in motor regions. Additionally, specific neural activation profiles regarding group and subprocess became apparent. Conclusions: Even though deficits in response inhibition are related to both ADHD and AUD, neural activation and recruited networks during response inhibition differ regarding both neuronal subprocesses and examined groups. While a replication of this study is needed in a larger sample, the results suggest that tasks have to be carefully selected when examining neural activation patterns of response inhibition either in research on various psychiatric disorders or transdiagnostic questions.
Introduction: In an emergency department, the majority of pediatric trauma patients present because of minor injuries. The aim of this study was to evaluate temporal changes in age-related injury pattern, trauma mechanism, and surgeries in pediatric patients. Methods: This retrospective study included patients < 18 years of age following trauma from 01/2009 to 12/2018 at a level I trauma center. They were divided into two groups: group A (A: 01/2009 to 12/2013) and group B (B: 01/2014 to 12/2018). Injury mechanism, injury pattern, and surgeries were analyzed. As major injuries fractures, dislocations, and organ injuries and as minor injuries contusions and superficial wounds were defined. Results: 23,582 patients were included (58% male, median age 8.2 years). There was a slight increase in patients comparing A (n = 11,557) and B (n = 12,025) with no difference concerning demographic characteristics. Significant more patients (A: 1.9%; B: 2.4%) were admitted to resuscitation room, though the number of multiple injured patients was not significantly different. In A (25.5%), major injuries occurred significantly less frequently than in B (27.0%), minor injuries occurred equally. Extremity fractures were significantly more frequent in B (21.5%) than in A (20.2%), peaking at 8–12 years. Most trauma mechanisms of both groups were constant, with a rising of sport injuries at 8–12 years. Conclusion: Although number of patients increases only slightly over a decade, there was a clear increase in major injuries, particularly extremity fractures, peaking at 8–12 years. At this age also sport accidents significantly increased. At least, admittance to resuscitation room rose but without an increase of multiple injured patients.
Introduction: Improvements in both musculoskeletal and non-musculoskeletal manifestations are important treatment goals in psoriatic arthritis (PsA). Objective: These post hoc analyses determined whether additional benefits related to various PsA domains are observed in patients simultaneously achieving 50% improvement in American College of Rheumatology criteria (ACR50) and 100% improvement in Psoriasis Area Severity Index (PASI100), the primary endpoint of the SPIRIT-H2H study. Methods: Patients with active PsA and psoriasis in SPIRIT-H2H (N = 566) were categorised into two sets of four response groups irrespective of treatment allocation (approved dosages of ixekizumab or adalimumab): patients who simultaneously achieved ACR50 and PASI100 response, achieved ACR50 response only, achieved PASI100 response only, or did not achieve ACR50 or PASI100 response after 24 and 52 weeks of treatment. Patients achieving simultaneous ACR50 and PASI100 response were compared with the other patient response groups at the corresponding time point for efficacy and health-related quality of life (HRQoL) outcomes. Results: Patients simultaneously achieving ACR50 and PASI100 responses at week 24 or 52 showed higher rates of ACR70 response, minimal disease activity, Disease Activity in Psoriatic Arthritis ≤ 4, resolution of enthesitis and dactylitis, and HRQoL improvement at weeks 24 and 52, respectively, than the other corresponding response groups at both time points. Conclusion: High levels of disease control, such as those obtained with simultaneous achievement of ACR50 and PASI100 response, were linked to better outcomes across a wide range of endpoints that are important for patients with PsA. Patients meeting this combined endpoint showed more comprehensive and thus greater control of disease activity.
Background: Due to the coronavirus disease 2019 (COVID-19) pandemic, interventions in the upper airways are considered high-risk procedures for otolaryngologists and their colleagues. The purpose of this study was to evaluate limitations in hearing and communication when using a powered air-purifying respirator (PAPR) system to protect against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) transmission and to assess the benefit of a headset. Methods: Acoustic properties of the PAPR system were measured using a head and torso simulator. Audiological tests (tone audiometry, Freiburg speech test, Oldenburg sentence test (OLSA)) were performed in normal-hearing subjects (n = 10) to assess hearing with PAPR. The audiological test setup also included simulation of conditions in which the target speaker used either a PAPR, a filtering face piece (FFP) 3 respirator, or a surgical face mask. Results: Audiological measurements revealed that sound insulation by the PAPR headtop and noise, generated by the blower-assisted respiratory protection system, resulted in significantly deteriorated hearing thresholds (4.0 ± 7.2 dB hearing level (HL) vs. 49.2 ± 11.0
Objectives: To evaluate the predictive value of volumetric bone mineral density (BMD) assessment of the lumbar spine derived from phantomless dual-energy CT (DECT)-based volumetric material decomposition as an indicator for the 2-year occurrence risk of osteoporosis-associated fractures. Methods: L1 of 92 patients (46 men, 46 women; mean age, 64 years, range, 19–103 years) who had undergone third-generation dual-source DECT between 01/2016 and 12/2018 was retrospectively analyzed. For phantomless BMD assessment, dedicated DECT postprocessing software using material decomposition was applied. Digital files of all patients were sighted for 2 years following DECT to obtain the incidence of osteoporotic fractures. Receiver operating characteristic (ROC) analysis was used to calculate cut-off values and logistic regression models were used to determine associations of BMD, sex, and age with the occurrence of osteoporotic fractures. Results: A DECT-derived BMD cut-off of 93.70 mg/cm3 yielded 85.45% sensitivity and 89.19% specificity for the prediction to sustain one or more osteoporosis-associated fractures within 2 years after BMD measurement. DECT-derived BMD was significantly associated with the occurrence of new fractures (odds ratio of 0.8710, 95% CI, 0.091–0.9375, p < .001), indicating a protective effect of increased DECT-derived BMD values. Overall AUC was 0.9373 (CI, 0.867–0.977, p < .001) for the differentiation of patients who sustained osteoporosis-associated fractures within 2 years of BMD assessment. Conclusions: Retrospective DECT-based volumetric BMD assessment can accurately predict the 2-year risk to sustain an osteoporosis-associated fracture in at-risk patients without requiring a calibration phantom. Lower DECT-based BMD values are strongly associated with an increased risk to sustain fragility fractures.
Key Points: Dual-energy CT–derived assessment of bone mineral density can identify patients at risk to sustain osteoporosis-associated fractures with a sensitivity of 85.45% and a specificity of 89.19%. The DECT-derived BMD threshold for identification of at-risk patients lies above the American College of Radiology (ACR) QCT guidelines for the identification of osteoporosis (93.70 mg/cm 3 vs 80 mg/cm 3 ).
To explore and describe attitudes and opinions towards suicidality in healthcare professionals (HCPs) working with oncological patients. Methods: A 48-item online questionnaire was developed and distributed to HCPs working with cancer patients. Three hundred fifty-four answered questionnaires were analyzed. Results: The majority of HCPs reported that they were able to understand why a cancer patient would commit suicide (87.8%) or would seek help from an assisted suicide organization (ASO; 83.9%). The understandable reasons were pain and physical impairments (51.4%), social isolation (19.8%), loss of control and autonomy (18.1%), terminal disease (17.2%), loss of meaning (15.3%), desperation (14.7%), and psychic distress (9.3%). Personal experiences with suicidality lead only 44.8% of HCPs to believe that thereby they would be better able to understand a patients’ wish for suicide. Religion was negatively associated with understanding of suicide and why a cancer patient would seek help from an ASO. Knowledge of suicidality was positively associated with why a cancer patient would seek help from an ASO. Conclusions: There is still little knowledge in oncology about the relation of HCPs’ attitudes toward suicidality in their patients and how those attitudes influence their behavior, especially care and treatment of patients. More research on this topic is needed. It stands to reason that more education about suicidality in cancer patients seems likely to improve understanding and attitudes and thereby influence care for cancer patients.
Background: Dual-source dual-energy computed tomography (DECT) offers the potential for opportunistic osteoporosis screening by enabling phantomless bone mineral density (BMD) quantification. This study sought to assess the accuracy and precision of volumetric BMD measurement using dual-source DECT in comparison to quantitative CT (QCT). Methods: A validated spine phantom consisting of three lumbar vertebra equivalents with 50 (L1), 100 (L2), and 200 mg/cm3 (L3) calcium hydroxyapatite (HA) concentrations was scanned employing third-generation dual-source DECT and QCT. While BMD assessment based on QCT required an additional standardised bone density calibration phantom, the DECT technique operated by using a dedicated postprocessing software based on material decomposition without requiring calibration phantoms. Accuracy and precision of both modalities were compared by calculating measurement errors. In addition, correlation and agreement analyses were performed using Pearson correlation, linear regression, and Bland-Altman plots. Results: DECT-derived BMD values differed significantly from those obtained by QCT (p < 0.001) and were found to be closer to true HA concentrations. Relative measurement errors were significantly smaller for DECT in comparison to QCT (L1, 0.94% versus 9.68%; L2, 0.28% versus 5.74%; L3, 0.24% versus 3.67%, respectively). DECT demonstrated better BMD measurement repeatability compared to QCT (coefficient of variance < 4.29% for DECT, < 6.74% for QCT). Both methods correlated well to each other (r = 0.9993; 95% confidence interval 0.9984–0.9997; p < 0.001) and revealed substantial agreement in Bland-Altman plots. Conclusions: Phantomless dual-source DECT-based BMD assessment of lumbar vertebra equivalents using material decomposition showed higher diagnostic accuracy compared to QCT.
We investigated the effects of sexual arousal induced by olfactory stimuli on the expression of neuromodulators, neurotransmitters and sexual steroid receptors in the suprachiasmatic nucleus (SCN, the circadian pacemaker of mammals) and other cerebral entities of Syrian hamsters (Mesocricetus auratus) compared to manual sleep deprivation and immobilization stress. The hamsters kept under a 12:12 hours (h) light:dark cycle were deprived of sleep by sexual stimulation, gentle manual handling or immobilization stress for 1 h at the beginning of the light phase and subsequently sacrificed at zeitgeber time 01:00, respectively; for comparison, hamsters were manually sleep deprived for 6 or 20 h or sacrificed after completing a full sleep phase. As demonstrated by immunohistochemistry, apart from various alterations after manual sleep deprivation, sexual stimulation caused down-regulation of arginine-vasopressin (AVP), vasointestinal peptide (VIP), serotonin (5-HT), substance P (SP), and met-enkephalin (ME) in the SCN. Somatostatin (SOM) was diminished in the medial periventricular nucleus (MPVN). In contrast, an increase in AVP was observed in the PVN, that of oxytocin (OXY) in the supraoptic nucleus (SON), of tyrosine-hydroxylase (TH) in the infundibular nucleus (IN), and dopamine beta-hydroxylase (DBH) in the A7 neuron population of the brain stem (A7), respectively. Testosterone in plasma was increased. The results indicate that sexual arousal extensively influences the neuropeptide systems of the SCN, suggesting an involvement of the SCN in reproductive behavior.
Rodent models of Parkinson’s disease are based on transgenic expression of mutant synuclein, deletion of PD genes, injections of MPTP or rotenone, or seeding of synuclein fibrils. The models show histopathologic features of PD such as Lewi bodies but mostly only subtle in vivo manifestations or systemic toxicity. The models only partly mimic a predominant loss of dopaminergic neurons in the substantia nigra. We therefore generated mice that express the transgenic diphtheria toxin receptor (DTR) specifically in DA neurons by crossing DAT-Cre mice with Rosa26 loxP-STOP-loxP DTR mice. After defining a well-tolerated DTx dose, DAT-DTR and DTR-flfl controls were subjected to non-toxic DTx treatment (5 × 100 pg/g) and subsequent histology and behavioral tests. DAT protein levels were reduced in the midbrain, and tyrosine hydroxylase-positive neurons were reduced in the substantia nigra, whereas the pan-neuronal marker NeuN was not affected. Despite the promising histologic results, there was no difference in motor function tests or open field behavior. These are tests in which double mutant Pink1−/−SNCAA53T Parkinson mice show behavioral abnormalities. Higher doses of DTx were toxic in both groups. The data suggest that DTx treatment in mice with Cre/loxP-driven DAT-DTR expression leads to partial ablation of DA-neurons but without PD-reminiscent behavioral correlates.
Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limitation may come from hematological rather than renal function, hematological peripheral blood stem cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression (≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle). Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied, and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range, 21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection seems to be feasible in NET with bone-marrow involvement and might be worth considering as a backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.
Gaining detailed knowledge about sex-related immunoregulation remains a crucial prerequisite for the development of adequate disease models and therapeutic strategies enabling personalized medicine. Here, the key parameter of the production of cytokines mediating disease resolution was investigated. Among these cytokines, STAT3-activating interleukin (IL)-22 is principally associated with recovery from tissue injury. By investigating paradigmatic acetaminophen-induced liver injury, we demonstrated that IL-22 expression is enhanced in female mice. Increased female IL-22 was confirmed at a cellular level using murine splenocytes stimulated by lipopolysaccharide or αCD3/CD28 to model innate or adaptive immunoactivation. Interestingly, testosterone or dihydrotestosterone reduced IL-22 production by female but not by male splenocytes. Mechanistic studies on PMA/PHA-stimulated T-cell-lymphoma EL-4 cells verified the capability of testosterone/dihydrotestosterone to reduce IL-22 production. Moreover, we demonstrated by chromatin immunoprecipitation that testosterone impairs binding of the aryl hydrocarbon receptor to xenobiotic responsive elements within the murine IL-22 promoter. Overall, female mice undergoing acute liver injury and cultured female splenocytes upon inflammatory activation display increased IL-22. This observation is likely related to the immunosuppressive effects of androgens in males. The data presented concur with more pronounced immunological alertness demonstrable in females, which may relate to the sex-specific course of some immunological disorders.
The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune response resulting in hyperinflammation. However, the factors predisposing individuals to severe disease remain poorly understood. Here, we show that levels of CD47, which is known to mediate immune escape in cancer and virus-infected cells, are elevated in SARS-CoV-2-infected Caco-2 cells, Calu-3 cells, and air−liquid interface cultures of primary human bronchial epithelial cells. Moreover, SARS-CoV-2 infection increases SIRPalpha levels, the binding partner of CD47, on primary human monocytes. Systematic literature searches further indicated that known risk factors such as older age and diabetes are associated with increased CD47 levels. High CD47 levels contribute to vascular disease, vasoconstriction, and hypertension, conditions that may predispose SARS-CoV-2-infected individuals to COVID-19-related complications such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury. Hence, age-related and virus-induced CD47 expression is a candidate mechanism potentially contributing to severe COVID-19, as well as a therapeutic target, which may be addressed by antibodies and small molecules. Further research will be needed to investigate the potential involvement of CD47 and SIRPalpha in COVID-19 pathology. Our data should encourage other research groups to consider the potential relevance of the CD47/ SIRPalpha axis in their COVID-19 research.
Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa). Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses. Results: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusions: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
Objective: The term ‘precision medicine’ describes a rational treatment strategy tailored to one person that reverses or modifies the disease pathophysiology. In epilepsy, single case and small cohort reports document nascent precision medicine strategies in specific genetic epilepsies. The aim of this multicentre observational study was to investigate the deeper complexity of precision medicine in epilepsy. Methods: A systematic survey of patients with epilepsy with a molecular genetic diagnosis was conducted in six tertiary epilepsy centres including children and adults. A standardised questionnaire was used for data collection, including genetic findings and impact on clinical and therapeutic management. Results: We included 293 patients with genetic epilepsies, 137 children and 156 adults, 162 females and 131 males. Treatment changes were undertaken because of the genetic findings in 94 patients (32%), including rational precision medicine treatment and/or a treatment change prompted by the genetic diagnosis, but not directly related to known pathophysiological mechanisms. There was a rational precision medicine treatment for 56 patients (19%), and this was tried in 33/56 (59%) and was successful (ie, >50% seizure reduction) in 10/33 (30%) patients. In 73/293 (25%) patients there was a treatment change prompted by the genetic diagnosis, but not directly related to known pathophysiological mechanisms, and this was successful in 24/73 (33%). Significance: Our survey of clinical practice in specialised epilepsy centres shows high variability of clinical outcomes following the identification of a genetic cause for an epilepsy. Meaningful change in the treatment paradigm after genetic testing is not yet possible for many people with epilepsy. This systematic survey provides an overview of the current application of precision medicine in the epilepsies, and suggests the adoption of a more considered approach.
Abstract: Neurophysiological measures of preparation and attention are often atypical in ADHD. Still, replicated findings that these measures predict which patients improve after Neurofeedback (NF), reveal neurophysiological specificity, and reflect ADHD-severity are limited. Methods: We analyzed children’s preparatory (CNV) and attentional (Cue-P3) brain activity and behavioral performance during a cued Continuous Performance Task (CPT) before and after slow cortical potential (SCP)-NF or semi-active control treatment (electromyogram biofeedback). Mixed-effects models were performed with 103 participants at baseline and 77 were assessed for pre-post comparisons focusing on clinical outcome prediction, specific neurophysiological effects of NF, and associations with ADHD-severity. Results: Attentional and preparatory brain activity and performance were non-specifically reduced after treatment. Preparatory activity in the SCP-NF group increased with clinical improvement. Several performance and brain activity measures predicted non-specific treatment outcome. Conclusion: Specific neurophysiological effects after SCP-NF were limited to increased neural preparation associated with improvement on ADHD-subscales, but several performance and neurophysiological measures of attention predicted treatment outcome and reflected symptom severity in ADHD. The results may help to optimize treatment.
Background: Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. Material and Methods: A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis. Results: After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. Conclusion: In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.
Background: To analyze postoperative, in-hospital, complication rates in patients with organ transplantation before radical prostatectomy (RP). Methods: From National Inpatient Sample (NIS) database (2000–2015) prostate cancer patients treated with RP were abstracted and stratified according to prior organ transplant versus nontransplant. Multivariable logistic regression models predicted in-hospital complications. Results: Of all eligible 202,419 RP patients, 216 (0.1%) underwent RP after prior organ transplantation. Transplant RP patients exhibited higher proportions of Charlson comorbidity index ≥2 (13.0% vs. 3.0%), obesity (9.3% vs. 5.6%, both p < 0.05), versus to nontransplant RP. Of transplant RP patients, 96 underwent kidney (44.4%), 44 heart (20.4%), 40 liver (18.5%), 30 (13.9%) bone marrow, <11 lung (<5%), and <11 pancreatic (<5%) transplantation before RP. Within transplant RP patients, rates of lymph node dissection ranged from 37.5% (kidney transplant) to 60.0% (bone marrow transplant, p < 0.01) versus 51% in nontransplant patients. Regarding in-hospital complications, transplant patients more frequently exhibited, diabetic (31.5% vs. 11.6%, p < 0.001), major (7.9% vs. 2.9%) cardiac complications (3.2% vs. 1.2%, p = 0.01), and acute kidney failure (5.1% vs. 0.9%, p < 0.001), versus nontransplant RP. In multivariable logistic regression models, transplant RP patients were at higher risk of acute kidney failure (odds ratio [OR]: 4.83), diabetic (OR: 2.81), major (OR: 2.39), intraoperative (OR: 2.38), cardiac (OR: 2.16), transfusion (OR: 1.37), and overall complications (1.36, all p < 0.001). No in-hospital mortalities were recorded in transplant patients after RP. Conclusions: Of all transplants before RP, kidney ranks first. RP patients with prior transplantation have an increased risk of in-hospital complications. The highest risk, relative to nontransplant RP patients appears to acute kidney failure.
The majority of excitatory synapses terminating on cortical neurons are found on dendritic spines. The geometry of spines, in particular the size of the spine head, tightly correlates with the strength of the excitatory synapse formed with the spine. Under conditions of synaptic plasticity, spine geometry may change, reflecting functional adaptations. Since the cytokine tumor necrosis factor (TNF) has been shown to influence synaptic transmission as well as Hebbian and homeostatic forms of synaptic plasticity, we speculated that TNF-deficiency may cause concomitant structural changes at the level of dendritic spines. To address this question, we analyzed spine density and spine head area of Alexa568-filled granule cells in the dentate gyrus of adult C57BL/6J and TNF-deficient (TNF-KO) mice. Tissue sections were double-stained for the actin-modulating and plasticity-related protein synaptopodin (SP), a molecular marker for strong and stable spines. Dendritic segments of TNF-deficient granule cells exhibited ∼20% fewer spines in the outer molecular layer of the dentate gyrus compared to controls, indicating a reduced afferent innervation. Of note, these segments also had larger spines containing larger SP-clusters. This pattern of changes is strikingly similar to the one seen after denervation-associated spine loss following experimental entorhinal denervation of granule cells: Denervated granule cells increase the SP-content and strength of their remaining spines to homeostatically compensate for those that were lost. Our data suggest a similar compensatory mechanism in TNF-deficient granule cells in response to a reduction in their afferent innervation.
Aim: It can be challenging to distinguish COVID-19 in children from other common infections. We set out to determine the rate at which children consulting a primary care paediatrician with an acute infection are infected with SARS-CoV-2 and to compare distinct findings. Method: In seven out-patient clinics, children aged 0–13 years with any new respiratory or gastrointestinal symptoms and presumed infection were invited to be tested for SARS-CoV-2. Factors that were correlated with testing positive were determined. Samples were collected from 25 January 2021 to 01 April 2021. Results: Seven hundred and eighty-three children participated in the study (median age 3 years and 0 months, range 1 month to 12 years and 11 months). Three hundred and fifty-eight were female (45.7%). SARS-CoV-2 RNA was detected in 19 (2.4%). The most common symptoms in children with as well as without detectable SARS-CoV-2 RNA were rhinitis, fever and cough. Known recent exposure to a case of COVID-19 was significantly correlated with testing positive, but symptoms or clinical findings were not. Conclusion: COVID-19 among the children with symptoms of an acute infection was uncommon, and the clinical presentation did not differ significantly between children with and without evidence of an infection with SARS-CoV-2.
Introduction: Adeno-associated virus (AAV)-based gene therapy for haemophilia presents a challenge to the existing structure of haemophilia centres and requires a rethink of current collaboration and information exchange with the aim of ensuring a system that is fit-for-purpose for advanced therapies to maximise benefits and minimise risks. In Europe, a certification process based on the number of patients and facilities is offered to the haemophilia centres by European Haemophilia Network (EUHANET). Aim and methods: This joint European Association for Haemophilia and Allied Disorders (EAHAD) and European Haemophilia Consortium (EHC) publication describes criteria for centres participating in gene therapy care that require a reassessment of the infrastructure of comprehensive care and provides an outlook on how these criteria can be implemented in the future work of haemophilia centres. Results: The core definition of a haemophilia treatment centre remains, but additional roles could be implemented. A modifiable ‘hub-and-spoke’ model addresses all aspects associated with gene therapy, including preparation and administration of the gene therapy product, determination of coagulation and immunological parameters, joint.
Introduction: Over the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for metastatic prostate cancer (mPCa). However, real-world data validating this effect within large-scale epidemiological data sets are scarce. We addressed this void. Materials and Methods: Men with de novo mPCa were identified and systemic chemotherapy status was ascertained within the Surveillance, Epidemiology, and End Results database (2004–2016). Patients were divided between historical (2004–2013) versus contemporary (2014–2016). Chemotherapy rates were plotted over time. Kaplan–Meier plots and Cox regression models with additional multivariable adjustments addressed overall and cancer-specific mortality. All tests were repeated in propensity-matched analyses. Results: Overall, 19,913 patients had de novo mPCa between 2004 and 2016. Of those, 1838 patients received chemotherapy. Of 1838 chemotherapy-exposed patients, 903 were historical, whereas 905 were contemporary. Chemotherapy rates increased from 5% to 25% over time. Median overall survival was not reached in contemporary patients versus was 24 months in historical patients (hazard ratio [HR]: 0.55, p < 0.001). After propensity score matching and additional multivariable adjustment (age, prostate-specific antigen, GGG, cT-stage, cN-stage, cM-stage, and local treatment) a HR of 0.55 (p < 0.001) was recorded. Analyses were repeated for cancer-specific mortality after adjustment for other cause mortality in competing risks regression models and recorded virtually the same findings before and after propensity score matching (HR: 0.55, p < 0.001). Conclusions: In mPCa patients, chemotherapy rates increased over time. A concomitant increase in survival was also recorded.
Purpose: To evaluate the impact of testing asymptomatic cancer patients, we analyzed all tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) before and during radiotherapy at a tertiary cancer center throughout the second wave of the pandemic in Germany. Methods: Results of all real-time polymerase chain reaction (RT-PCR) tests for SARS-CoV 2 performed at our radio-oncology department between 13 October 2020 and 11 March 2021 were included. Clinical data and anamnestic information at the time of testing were documented and examined for (i) the presence of COVID-19-related symptoms and (ii) virus-related anamnesis (high-risk [prior positive test or contact to a positive tested person within the last 14 days] or low-risk [inconspicuous anamnesis within the last 14 days]). Results: A total of 1056 SARS-CoV 2 tests in 543 patients were analyzed. Of those, 1015 tests were performed in asymptomatic patients and 41 tests in patients with COVID-19-associated symptoms. Two of 940 (0.2%) tests in asymptomatic patients with low-risk anamnesis and three of 75 (4.0%) tests in asymptomatic patients with high-risk anamnesis showed a positive result. For symptomatic patients, SARS-CoV 2 was detected in three of 36 (8.3%) low-risk and three of five (60.0%) high-risk tests. Conclusion: To the best of our knowledge, this is the first study evaluating the correlation between individual risk factors and positivity rates of SARS-CoV 2 tests in cancer patients. The data demonstrate that clinical and anamnestic assessment is a simple and effective measure to distinctly increase SARS-CoV 2 test efficiency. This might enable cancer centers to adjust test strategies in asymptomatic patients, especially when test resources are scarce.
Interpretation bias and dysfunctional social assumptions are proposed to play a pivotal role in the development and maintenance of social phobia (SP), especially in youth. In this study, we aimed to investigate disorder-specific implicit assumptions of rejection and implicit interpretation bias in youth with severe, chronic SP and healthy controls (CG). Twenty-seven youth with SP in inpatient/day-care treatment (M age = 15.6 years, 74% female) and 24 healthy controls (M age = 15.7 years, 54% female) were included. The Implicit Association Test (IAT) and the Affect Misattribution Procedure (AMP) were completed to assess implicit assumptions and interpretation bias related to the processing of social and affective stimuli. No group differences were observed for the IAT controlling for depressive symptoms in the analyses. However, group differences were found regarding interpretation bias (p = .017, η2p = .137). Correlations between implicit scores and explicit questionnaire results were medium to large in the SP group (r =|.28| to |.54|, pall ≤ .05), but lower in the control group (r =|.04| to |.46|, pall ≤ .05). Our results confirm the finding of an interpretation bias in youth SP, especially regarding the implicit processing of faces, whereas implicit dysfunctional social assumptions of being rejected do not seem to be specific for SP. Future research should investigate the causal relationship of assumptions/interpretation bias and SP.
Estimating the age of the developmental stages of the blow fly Calliphora vicina (Diptera: Calliphoridae) is of forensic relevance for the determination of the minimum post-mortem interval (PMImin). Fly eggs and larvae can be aged using anatomical and morphological characters and their modification during development. However, such methods can only hardly be applied for aging fly pupae. Previous study described age estimation of C. vicina pupae using gene expression, but just when reared at constant temperatures, but fluctuating temperatures represent a more realistic scenario at a crime scene. Therefore, age-dependent gene expression of C. vicina pupae were compared at 3 fluctuating and 3 constant temperatures, the latter representing the mean values of the fluctuating profiles. The chosen marker genes showed uniform expression patterns during metamorphosis of C. vicina pupae bred at different temperature conditions (constant or fluctuating) but the same mean temperature (e.g. constant 10 °C vs. fluctuating 5–15 °C). We present an R-based statistical tool, which enables estimation of the age of the examined pupa based on the analysed gene expression data.
The physiotherapist plays an essential role for people with haemophilia, an inherited bleeding disease responsible for musculoskeletal complications. Yet, with the advent of new and advanced therapies, the medical landscape is changing, and physiotherapy must adapt alongside. This paper considers whether there will still be a need for physiotherapy in the era of advanced therapies, and discusses ways in which services should evolve to complement emerging treatment paradigms for haemostasis in people with haemophilia. Ultimately, physiotherapy will remain an important element of care, even for people with little joint damage and low risks in the era of the new mild phenotype. However, competencies will need to evolve, and physiotherapists in both primary care and specialist treatment centres should work with haematology colleagues to develop more sensitive tools for detecting early joint changes. Physiotherapists will also play a crucial role in counselling and physically coaching, monitoring the musculoskeletal status of people with haemophilia who have transitioned to new treatments.
Given the ongoing global SARS-CoV-2-vaccination efforts, clinical awareness needs to be raised regarding the possibility of an increased incidence of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia in patients with intracerebral hemorrhage (ICH) secondary to cerebral sinus and vein thrombosis (CVT) requiring (emergency) neurosurgical treatment in the context of vaccine-induced immune thrombotic thrombocytopenia (VITT). Only recently, an association of vaccinations and cerebral sinus and vein thrombosis has been described. In a number of cases, neurosurgical treatment is warranted for these patients and special considerations are warranted when addressing the perioperative coagulation. We, herein, describe the past management of patients with VITT and established a literature-guided algorithm for the treatment of patients when addressing the impaired coagulation in these patients. Increasing insights addressing the pathophysiology of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia guide physicians in developing an interdisciplinary algorithm taking into account the special considerations of this disease.
Background: Both selective mutism (SM) and social anxiety disorder (SAD) are severe pediatric anxiety disorders with the common trait of behavioral inhibition (BI). The underlying pathophysiology of these disorders remains poorly understood, however converging evidence suggests that alterations in several peripheral molecular pathways might be involved. In a pilot study, we investigated alterations in plasma molecular markers (dipeptidyl peptidase-4 [DPPIV], interleukin-6 [IL-6], tumor necrosis factor-β [TNF-β] and neuropeptide-Y [NPY]) in children with SM, SAD, and healthy controls, as well as the correlation of these markers to symptom severity. Methods: We included 51 children and adolescents (aged 5–18 years; n = 29 girls): n = 20 children in the SM-, n = 16 in the SAD- and n = 15 in the control-group (CG). Peripheral blood samples were analyzed for DPPIV, IL-6, TNF-β, and NPY concentrations. Diverse psychometric measures were used for BI, anxiety, and mutism symptoms. Results: Lower DPPIV-levels were correlated with more anxiety symptoms. However, we could not find a difference in any molecular marker between the patients with SAD and SM in comparison to the CG. Conclusion: DPPIV is proposed as relevant marker for child and adolescent anxiety. Investigating the pathophysiology of SM and SAD focusing on state and trait variables as anxiety or BI might help better understanding the underlying mechanisms of these disorders. Further studies with especially larger cohorts are needed to validate the current pilot-findings.
Since the survival rates of pediatric patients undergoing cancer treatment or hematopoietic stem cell transplantation (HSCT) have increased rapidly in recent decades, the late effects of treatment are now an important focus of patient care. Access to fertility preservation (FP) procedures as well as their financing differs considerably across Europe. However, some countries in Europe have recently changed the legal basis for financing FP procedures; therefore, the implementation of structures is mandatory to give patients access to FP. In this prospective cohort study, we characterized the process for establishing pediatric fertility counseling, including the development of an in-house standard procedure for recommendations regarding FP with potentially gonadotoxic treatment and valuating data from all FP counseling sessions. All data concerning patient characteristics (pubertal status, disease group) and recommendation of FP measures were prospectively collected and adoption of FP measures analyzed. Prior to the establishment of a structured process for FP in our pediatric oncology and stem cell transplantation center, there was no standardized FP counseling. We demonstrate that with the establishment of an inhouse standard procedure, it is possible to give consistent yet individualized FP counseling to approximately 90% of our patients facing gonadotoxic treatment, counseling over 200 patients between 2017 and 2019. This pilot study could potentially be adapted in other pediatric hematology, oncology, and stem cell transplantation centers to allow a more standardized handling of FP counseling for all patients facing gonadotoxic treatment.
Purpose: To investigate short-term (3 months follow-up) changes in visual quality following Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy (FED). Methods: In this prospective institutional case series, 51 patients that underwent DMEK for FED were included. Assessment included the Quality of Vision (QoV) questionnaire preoperatively, at 1 month, and 3 months after surgery. Secondary outcome measures were anterior segment parameters acquired by Scheimpflug imaging, corrected distance visual acuity (CDVA), and endothelial cell density (ECD). Results: Glare, hazy vision, blurred vision, and daily fluctuation in vision were the symptoms mostly reported preoperatively. All symptoms demonstrated a significant reduction of item scores for severity, frequency, and bothersome in the course after DMEK (P < 0.01). Glare and fluctuation in vision remained to some extent during the follow-up period (median score = 1). Preoperatively, corneal densitometry correlated moderately to weakly with severity of hazy vision (rs = 0.39; P = 0.03) and frequency (rs = 0.26; P = 0.02) as well as severity (rs = 0.27; P = 0.03) of blurry vision. CDVA and central corneal thickness (CCT) did not correlate with visual complains. Conclusions: Following DMEK for FED, patient-reported visual symptoms assessed by the QoV questionnaire represent a useful tool providing valuable information on the impact of DMEK on visual quality that cannot be directly estimated by morphological parameters and visual acuity only.
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1. Methods: CNDAC was tested in 13 acute myeloid leukaemia (AML) cell lines, in 26 acute lymphoblastic leukaemia (ALL) cell lines, ten AML sublines adapted to various antileukaemic drugs, 24 single cell-derived clonal AML sublines, and primary leukaemic blasts from 24 AML patients. Moreover, 24 CNDAC-resistant sublines of the AML cell lines HL-60 and PL-21 were established. The SAMHD1 gene was disrupted using CRISPR/Cas9 and SAMHD1 depleted using RNAi, and the viral Vpx protein. Forced DCK expression was achieved by lentiviral transduction. SAMHD1 promoter methylation was determined by PCR after treatment of genomic DNA with the methylation-sensitive HpaII endonuclease. Nucleoside (analogue) triphosphate levels were determined by LC-MS/MS. CNDAC interaction with SAMHD1 was analysed by an enzymatic assay and by crystallisation. Results: Although the cytosine analogue CNDAC was anticipated to inhibit SAMHD1, SAMHD1 mediated intrinsic CNDAC resistance in leukaemia cells. Accordingly, SAMHD1 depletion increased CNDAC triphosphate (CNDAC-TP) levels and CNDAC toxicity. Enzymatic assays and crystallisation studies confirmed CNDAC-TP to be a SAMHD1 substrate. In 24 CNDAC-adapted acute myeloid leukaemia (AML) sublines, resistance was driven by DCK (catalyses initial nucleoside phosphorylation) loss. CNDAC-adapted sublines displayed cross-resistance only to other DCK substrates (e.g. cytarabine, decitabine). Cell lines adapted to drugs not affected by DCK or SAMHD1 remained CNDAC sensitive. In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine and CNDAC resistance. Conclusion: Intrinsic and acquired resistance to CNDAC and related nucleoside analogues are driven by different mechanisms. The lack of cross-resistance between SAMHD1/ DCK substrates and non-substrates provides scope for next-line therapies after treatment failure.
Cancer therapies have experienced significant advances in recent years. While conventional cytotoxic chemotherapy has long been the cornerstone for the treatment of many tumor entities, uprising immunotherapies have revolutionized the therapeutic landscape. Among them, immune checkpoint inhibitors (ICIs) with their demonstrated increased overall survival rates and response rates in cancer patients are now FDA-approved for metastatic melanoma and multiple other malignancies. Despite their clinical benefit in cancer therapies, ICIs can induce unique autoimmune-like toxicities known as immune-related adverse events (irAEs), which can involve any organ system including the nervous system. Although neurotoxicities are rare complications of ICI therapy they are often severe and can lead to long-term disability or even death if left untreated.
Neurological irAEs exhibit a broad spectrum of clinical presentations affecting the entire nervous system. Diagnosing neurological irAEs is often challenging as symptoms and laboratory findings can be uncharacteristic for common neurological disorders and clinical experience with ICI-mediated toxicities is still limited. In light of expanding clinical indications for ICIs, physicians will encounter ICI-mediated neurotoxicities more frequently. Thus, thorough characterizations of the diverse set of neurological irAEs are essential for optimal patient care, the prevention of severe ICI-mediated complications, and the development of diagnostic and therapeutic algorithms. This work portrays the clinical presentation, management and outcome of neurological irAEs following ICI therapies.
Patients with neurotoxicities related to ICIs who presented at the Yale New Haven Hospital between January 2014 and June 2018 were retrospectively identified from the quality control database. A comprehensive chart review was performed and data regarding patient demographics, medical history, ICI regimen and neurotoxicity were recorded. In total, 18 patients with neurological irAEs following ICI therapy for melanoma, small cell lung cancer, non-small cell lung cancer, and Merkel-cell carcinoma were identified. Neurotoxicities included central nervous system disorders comprising central demyelinating disorder,autoimmune encephalitis predominantly affecting the grey matter, and aseptic meningitis. Peripheral nervous system toxicities included sensorimotor polyneuropathy and myasthenia gravis. Cases of hypophysitis were also recorded. Time to onset of neurological irAEs ranged from 1 to72 weeks with a median of five weeks. In all patients ICIs were held and steroids initiated. Additional immunomodulatory therapies were required in nine patients. Sixteen of 18 patients showed neurological improvement. Fourteen patients had highgrade neurotoxicity (grade 3-4), six of whom deceased due to cancer progression, while none of the low-grade neurotoxicity patients (grade 1-2) died. High-grade neurotoxicity was identified as a negative prognostic marker for overall survival (p = 0.046).
This work shows that neurotoxicities present early-onset, rapidly progressive complications of ICIs with a broad spectrum of clinical phenotypes affecting the central nervous system, peripheral nervous system, and neuroendocrine system. A high index of caution for neurological irAEs is warranted throughout ICI therapy as timely diagnosis and management can reduce morbidity and mortality. Randomized clinical trials are needed to develop standardized diagnostic and therapeutic algorithms of ICI-induced neurotoxicities.
Transcatheter left atrial appendage occlusion (LAAO) is non-inferior to vitamin K antagonists (VKAs) in preventing thromboembolic events in atrial fibrillation (AF). Non-vitamin K antagonists (NOACs) have an improved safety profile over VKAs; however, evidence regarding their effect on cardiovascular and neurological outcomes relative to LAAO is limited. Up-to-date randomized trials or propensity-score-matched data comparing LAAO vs. NOACs in high-risk patients with AF were pooled in our study. A total of 2849 AF patients (LAAO: 1368, NOACs: 1481, mean age: 75 ± 7.5 yrs, 63.5% male) were enrolled. The mean CHA2DS2-VASc score was 4.3 ± 1.7, and the mean HAS-BLED score was 3.4 ± 1.2. The baseline characteristics were comparable between the two groups. In the LAAO group, the success rate of device implantation was 98.8%. During a mean follow-up of 2 years, as compared with NOACs, LAAO was associated with a significant reduction of ISTH major bleeding (p = 0.0002). There were no significant differences in terms of ischemic stroke (p = 0.61), ischemic stroke/thromboembolism (p = 0.63), ISTH major and clinically relevant minor bleeding (p = 0.73), cardiovascular death (p = 0.63), and all-cause mortality (p = 0.71). There was a trend toward reduction of combined major cardiovascular and neurological endpoints in the LAAO group (OR: 0.84, 95% CI: 0.64–1.11, p = 0.12). In conclusion, for high-risk AF patients, LAAO is associated with a significant reduction of ISTH major bleeding without increased ischemic events, as compared to “contemporary NOACs”. The present data show the superior role of LAAO over NOACs among high-risk AF patients in terms of reduction of major bleeding; however, more randomized controlled trials are warranted.
Simple Summary: The role of transcriptionally deregulated miRNAs (microRNAs) in classical Hodgkin lymphoma (cHL) is still not fully understood. To address this issue, we have performed global miRNA expression profiling of commonly used cHL cell lines and we present a complete cHL miRNome (microRNome). Within this group, we identify miRNAs recurrently deregulated in cHL cell lines, and compare them to non-Hodgkin lymphoma cell lines and sorted normal CD77+ germinal centre B-cells. Moreover, we show that several of the recurrently overexpressed miRNAs in cHL cell lines, and also primary microdissected HRS (Hodgkin and Reed-Sternberg) cells, target known B-cell-related transcription factors and NF-κB inhibitors. These findings provide evidence that deregulated miRNAs contribute to the loss of B-cell phenotype and NF-κB activation observed in this lymphoma.
Abstract: A hallmark of classical Hodgkin lymphoma (cHL) is the attenuation of B-cell transcription factors leading to global transcriptional reprogramming. The role of miRNAs (microRNAs) involved in this process is poorly studied. Therefore, we performed global miRNA expression profiling using RNA-seq on commonly used cHL cell lines, non-Hodgkin lymphoma cell lines and sorted normal CD77+ germinal centre B-cells as controls and characterized the cHL miRNome (microRNome). Among the 298 miRNAs expressed in cHL, 56 were significantly overexpressed and 23 downregulated (p < 0.05) compared to the controls. Moreover, we identified five miRNAs (hsa-miR-9-5p, hsa-miR-24-3p, hsa-miR-196a-5p, hsa-miR-21-5p, hsa-miR-155-5p) as especially important in the pathogenesis of this lymphoma. Target genes of the overexpressed miRNAs in cHL were significantly enriched (p < 0.05) in gene ontologies related to transcription factor activity. Therefore, we further focused on selected interactions with the SPI1 and ELF1 transcription factors attenuated in cHL and the NF-ĸB inhibitor TNFAIP3. We confirmed the interactions between hsa-miR-27a-5p:SPI1, hsa-miR-330-3p:ELF-1, hsa-miR-450b-5p:ELF-1 and hsa-miR-23a-3p:TNFAIP3, which suggest that overexpression of these miRNAs contributes to silencing of the respective genes. Moreover, by analyzing microdissected HRS cells, we demonstrated that these miRNAs are also overexpressed in primary tumor cells. Therefore, these miRNAs play a role in silencing the B-cell phenotype in cHL.
Preeclampsia (PE), a gestational hypertensive disease originating from the placenta, is characterized by an imbalance of various cellular processes. The cell cycle regulator p21Cip1/CDKN1A (p21) and its family members p27 and p57 regulate signaling pathways fundamental to placental development. The aim of the present study was to enlighten the individual roles of these cell cycle regulators in placental development and their molecular involvement in the pathogenesis of PE. The expression and localization of p21, phospho-p21 (Thr-145), p27, and p57 was immunohistochemically analyzed in placental tissues from patients with early-onset PE, early-onset PE complicated by the HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome as well as late-onset PE compared to their corresponding control tissues from well-matched women undergoing caesarean sections. The gene level was evaluated using real-time quantitative PCR. We demonstrate that the delivery mode strongly influenced placental gene expression, especially for CDKN1A (p21) and CDKN1B (p27), which were significantly upregulated in response to labor. Cell cycle regulators were highly expressed in first trimester placentas and impacted by hypoxic conditions. In support of these observations, p21 protein was abundant in trophoblast organoids and hypoxia reduced its gene expression. Microarray analysis of the trophoblastic BeWo cell line depleted of p21 revealed various interesting candidate genes and signaling pathways for the fusion process. The level of p21 was reduced in fusing cytotrophoblasts in early-onset PE placentas and depletion of p21 led to reduced expression of fusion-related genes such as syncytin-2 and human chorionic gonadotropin (β-hCG), which adversely affected the fusion capability of trophoblastic cells. These data highlight that cell cycle regulators are important for the development of the placenta. Interfering with p21 influences multiple pathways related to the pathogenesis of PE.
Although anti-cancer properties of the natural compound curcumin have been reported, low absorption and rapid metabolisation limit clinical use. The present study investigated whether irradiation with visible light may enhance the inhibitory effects of low-dosed curcumin on prostate cancer cell growth, proliferation, and metastasis in vitro. DU145 and PC3 cells were incubated with low-dosed curcumin (0.1–0.4 µg/mL) and subsequently irradiated with 1.65 J/cm2 visible light for 5 min. Controls remained untreated and/or non-irradiated. Cell growth, proliferation, apoptosis, adhesion, and chemotaxis were evaluated, as was cell cycle regulating protein expression (CDK, Cyclins), and integrins of the α- and β-family. Curcumin or light alone did not cause any significant effects on tumor growth, proliferation, or metastasis. However, curcumin combined with light irradiation significantly suppressed tumor growth, adhesion, and migration. Phosphorylation of CDK1 decreased and expression of the counter-receptors cyclin A and B was diminished. Integrin α and β subtypes were also reduced, compared to controls. Irradiation distinctly enhances the anti-tumor potential of curcumin in vitro and may hold promise in treating prostate cancer.
Sphingosine 1 phosphate (S1P) lyase (Sgpl1) catalyses the irreversible cleavage of S1P and thereby the last step of sphingolipid degradation. Loss of Sgpl1 in humans and mice leads to accumulation of sphingolipids and multiple organ injuries. Here, we addressed the role of hepatocyte Sgpl1 for regulation of sphingolipid homoeostasis by generating mice with hepatocyte-specific deletion of Sgpl1 (Sgpl1HepKO mice). Sgpl1HepKO mice had normal body weight, liver weight, liver structure and liver enzymes both at the age of 8 weeks and 8 months. S1P, sphingosine and ceramides, but not glucosylceramides or sphingomyelin, were elevated by ~1.5–2-fold in liver, and this phenotype did not progress with age. Several ceramides were elevated in plasma, while plasma S1P was normal. Interestingly, S1P and glucosylceramides, but not ceramides, were elevated in bile of Sgpl1HepKO mice. Furthermore, liver cholesterol was elevated, while LDL cholesterol decreased in 8-month-old mice. In agreement, the LDL receptor was upregulated, suggesting enhanced uptake of LDL cholesterol. Expression of peroxisome proliferator-activated receptor-γ, liver X receptor and fatty acid synthase was unaltered. These data show that mouse hepatocytes largely compensate the loss of Sgpl1 by secretion of accumulating sphingolipids in a specific manner into blood and bile, so that they can be excreted or degraded elsewhere.
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of fenfluramine (FFA) for the treatment of seizures in DS, patients in Germany could receive treatment under a compassionate use program (CUP). Methods: We conducted a multicenter, retrospective, observational study to describe the efficacy, tolerability, and retention of FFA within the CUP. Patients received add-on therapy with oral FFA gradually titrated to a target dose between .13 and .7 mg/kg/day Results: Overall, 78 patients with DS (median age = 8.0 years, range = 2.1–46.0; 53% female, median concomitant antiseizure medications [ASMs] = 3) were treated with FFA for a median duration of 255.5 days (range = 31–572). Responder rates (a ≥50% reduction; n = 78) and seizure-freedom rates at 3 months were 68% and 14% for total seizures, respectively, and 67% and 23% for generalized tonic–clonic seizures. Responder rates were consistent at 6 and 12 months (n = 66 and n = 43, respectively). Median seizure days per month significantly decreased from 10.0 (range = .5–30) to 3.0 (range = 0–30) in the 3-month period before and after FFA treatment (p < .001). Significantly fewer patients reported at least one episode of status epilepticus (28% vs. 14% patients before and after FFA initiation, p = .005). During FFA treatment, 35 (45%) patients were able to discontinue a concomitant ASM. At the last follow-up date, 66 (85%) patients remained on treatment with FFA. The most common adverse events were somnolence (36%), decreased appetite (22%), and ataxia (8%). Forty-eight (62%) patients were reported as having a meaningful global clinical improvement. Significance: In a large cohort of patients, FFA demonstrated efficacy across a range of outcomes including clinically significant reductions in convulsive seizures, and was well tolerated, providing valuable information for real-world practice.
Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa). Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses. Results: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusions: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
The scope of extracorporeal membrane oxygenation (ECMO) is expanding, nevertheless, pharmacokinetics in patients receiving cardiorespiratory support are fairly unknown leading to unpredictable drug concentrations. Currently, there are no clear guidelines for antibiotic dosing during ECMO. This study aims to evaluate the pharmacokinetics (PK) of cefazolin in patients undergoing ECMO treatment. Total and unbound plasma cefazolin concentration of critically ill patients on veno-arterial ECMO were determined. Observed PK was compared to dose recommendations calculated by an online available, free dosing software. Concentration of cefazolin varied broadly despite same dosage in all patients. The mean total and unbound plasma concentration were high showing significantly (p = 5.8913 E−09) greater unbound fraction compared to a standard patient. Cefazolin clearance was significantly (p = 0.009) higher in patients with preserved renal function compared with CRRT. Based upon the calculated clearance, the use of dosing software would have led to lower but still sufficient concentrations of cefazolin in general. Our study shows that a “one size fits all” dosing regimen leads to excessive unbound cefazolin concentration in these patients. They exhibit high PK variability and decreased cefazolin clearance on ECMO appears to compensate for ECMO- and critical illness-related increases in volume of distribution.
Peri-implantitis: summary and consensus statements of group 3. The 6th EAO Consensus Conference 2021
(2021)
Objective: To evaluate the influence of implant and prosthetic components on peri-implant tissue health. A further aim was to evaluate peri-implant soft-tissue changes following surgical peri-implantitis treatment. Materials and methods: Group discussions based on two systematic reviews (SR) and one critical review (CR) addressed (i) the influence of implant material and surface characteristics on the incidence and progression of peri-implantitis, (ii) implant and restorative design elements and the associated risk for peri-implant diseases, and (iii) peri-implant soft-tissue level changes and patient-reported outcomes following peri-implantitis treatment. Consensus statements, clinical recommendations, and implications for future research were discussed within the group and approved during plenary sessions. Results: Data from preclinical in vivo studies demonstrated significantly greater radiographic bone loss and increased area of inflammatory infiltrate at modified compared to non-modified surface implants. Limited clinical data did not show differences between modified and non-modified implant surfaces in incidence or progression of peri-implantitis (SR). There is some evidence that restricted accessibility for oral hygiene and an emergence angle of >30 combined with a convex emergence profile of the abutment/prosthesis are associated with an increased risk for peri-implantitis (CR). Reconstructive therapy for peri-implantitis resulted in significantly less soft-tissue recession, when compared with access flap. Implantoplasty or the adjunctive use of a barrier membrane had no influence on the extent of peri-implant mucosal recession following peri-implantitis treatment (SR).
Background: Treatment of acute stroke is highly time-dependent and performed by a multiprofessional, interdisciplinary team. Interface problems are expectable and issues relevant to patient safety are omnipresent. The Safety Attitudes Questionnaire (SAQ) is a validated and widely used instrument to measure patient safety climate. The objective of this study was to evaluate the SAQ for the first time in the context of acute stroke care. Methods: A survey was carried out during the STREAM trial (NCT 032282) at seven university hospitals in Germany from October 2017 to October 2018. The anonymous survey included 33 questions (5-point Likert scale, 1 = disagree to 5 = agree) and addressed the entire multiprofessional stroke team. Statistical analyses were used to examine psychometric properties as well as descriptive findings. Results: 164 questionnaires were completed yielding a response rate of 66.4%. 67.7% of respondents were physicians and 25.0% were nurses. Confirmatory Factor Analysis revealed that the original 6-factor structure fits the data adequately. The SAQ for acute stroke care showed strong internal consistency (α = 0.88). Exploratory analysis revealed differences in scores on the SAQ dimensions when comparing physicians to nurses and when comparing physicians according to their duration of professional experience. Conclusion: The SAQ is a helpful and well-applicable tool to measure patient safety in acute stroke care. In comparison to other high-risk fields in medicine, patient safety climate in acute stroke care seems to be on a similar level with the potential for further improvements. Trial registration: www.ClinicalTrials.gov Identifier: NCT032282.
Hematopoietic stem cell transplantation (HSCT) is widely used in pediatric patients as a successful curative therapy for life-threatening conditions. The treatment is intensive, with risks of serious complications and lethal outcomes. This study aimed to provide insight into current data on the place and cause of death of transplanted children, the available specialized pediatric palliative care services (SPPCS), and what services HSCT professionals feel the SPPCS team should provide. First, a retrospective database analysis on the place and cause of death of transplanted pediatric HSCT patients was performed. Second, a survey was performed addressing the availability of and views on SPPCS among HSCT professionals. Database analysis included 233 patients of whom the majority died in-hospital: 38% in the pediatric intensive care unit, 20% in HSCT units, 17% in other hospitals, and 14% at home or in a hospice (11% unknown). For the survey, 98 HSCT professionals from 54 centers participated. Nearly all professionals indicated that HSCT patients should have access to SPPCS, especially for pain management, but less than half routinely referred to this service at an early stage. We, therefore, advise HSCT teams to integrate advance care planning for pediatric HSCT patients actively, ideally from diagnosis, to ensure timely SPPCS involvement and maximize end-of-life preparation.
Platelets comprise a highly interactive immune cell subset of the circulatory system traditionally known for their unique haemostatic properties. Although platelets are considered as a vault of growth factors, cytokines and chemokines with pivotal role in vascular regeneration and angiogenesis, the exact mechanisms by which they influence vascular endothelial cells (ECs) function remain underappreciated. In the present study, we examined the role of human IL-17A/IL-17RA axis in platelet-mediated pro-angiogenic responses. We reveal that IL-17A receptor (IL-17RA) mRNA is present in platelets transcriptome and a profound increase is documented on the surface of activated platelets. By quantifying the protein levels of several factors, involved in angiogenesis, we identified that IL-17A/IL17RA axis selectively induces the release of vascular endothelial growth factor, interleukin -2 and -4, as well as monocyte chemoattractant protein -1 from treated platelets. However, IL-17A exerted no effect on the release of IL-10, an anti-inflammatory factor with potentially anti-angiogenic properties, from platelets. Treatment of human endothelial cell two-dimensional tubule networks or three-dimensional spheroid and mouse aortic ring structures with IL-17A-induced platelet releasate evoked pro-angiogenic responses of ECs. Our findings suggest that IL-17A may critically affect platelet release of pro-angiogenic factors driving ECs towards a pro-angiogenic state.
Container-breeding Aedes spp. (Diptera: Culicidae) mosquitoes can be surveilled at low cost using ovitraps. Hence, this method is a preferred monitoring approach of dengue vectors in low-resource settings. The ovitraps consist of a cup filled with water and an oviposition substrate for female mosquitoes. The attractiveness of the substrates for female mosquitoes can greatly differ due to differences in texture, color, and smell of the materials used. We compare four oviposition substrates, which are all low priced, easy to transport, and easy to purchase, to maximize the success of Aedes egg sampling. Sampled egg material is often reared to adulthood for further taxonomic identification and transported to (international) laboratories for specialized vector research. Here we introduce a transport technique for sampled eggs. In addition, we explored the impact of international transport by means of a bilateral hatching experiment in Nepal, the country of origin, and in Germany, in a laboratory specialized in ecophysiological research. The best low-cost oviposition substrate for the dengue vectors Aedes albopictus (Skuse) and Aedes aegypti (L.) was found to be a white cotton sheet. The introduced transport technique of sampled eggs is easy to build from laboratory and household materials and ensures good transport conditions (i.e., temperature and relative humidity). Even under good temperature (17.4–31.0 °C) and humidity conditions (58.9–94.2%), hatching success of eggs was found to be reduced after international transport to Germany when compared to the hatching success of eggs in Nepal. We postulate that air pressure during international transport may have reduced the hatching success and strongly recommend pressure-regulated transport boxes for egg transport via airplane. As the proposed operation procedure is useful in assisting the monitoring of Ae. albopictus and Ae. aegypti in low-resource settings, Aedes researchers are encouraged to follow it for the sampling and transport of Aedes eggs.
Background: One of the lesser recognized complications of diabetes mellitus are musculoskeletal (MSK) complications of the upper and lower extremity. No prevalence studies have been conducted in general practice. Thus, the aim of this study was to investigate the prevalence of upper extremity MSK disorders in patients with type 2 diabetes (T2DM) in the Netherlands. Methods: We conducted a cross-sectional study with two different approaches, namely a representative Dutch primary care medical database study and a questionnaire study among patients with T2DM. Results: In the database study, 2669 patients with T2DM and 2669 non-diabetes patients were included. MSK disorders were observed in 16.3% of patients with T2DM compared to 11.2% of non-diabetes patients (p < 0.001, OR 1.53, 95% CI 1.31, 1.80). In the questionnaire study, 200 patients with T2DM were included who reported a lifetime prevalence of painful upper extremity body sites for at least four weeks of 67.3%. Conclusion: We found that upper extremity MSK disorders have a high prevalence in Dutch patients with T2DM presenting in general practice. The prevalence ranges from 16% based on GP registered disorders and complaints to 67% based on self-reported diagnosis and pain. Early detection and treatment of these disorders may play a role in preventing the development of chronic MSK disorders.
Biological exploration of early biomarkers for chronic kidney disease (CKD) in (pre)diabetic individuals is crucial for personalized management of diabetes. Here, we evaluated two candidate biomarkers of incident CKD (sphingomyelin (SM) C18:1 and phosphatidylcholine diacyl (PC aa) C38:0) concerning kidney function in hyperglycemic participants of the Cooperative Health Research in the Region of Augsburg (KORA) cohort, and in two biofluids and six organs of leptin receptor-deficient (db/db) mice and wild type controls. Higher serum concentrations of SM C18:1 and PC aa C38:0 in hyperglycemic individuals were found to be associated with lower estimated glomerular filtration rate (eGFR) and higher odds of CKD. In db/db mice, both metabolites had a significantly lower concentration in urine and adipose tissue, but higher in the lungs. Additionally, db/db mice had significantly higher SM C18:1 levels in plasma and liver, and PC aa C38:0 in adrenal glands. This cross-sectional human study confirms that SM C18:1 and PC aa C38:0 associate with kidney dysfunction in pre(diabetic) individuals, and the animal study suggests a potential implication of liver, lungs, adrenal glands, and visceral fat in their systemic regulation. Our results support further validation of the two phospholipids as early biomarkers of renal disease in patients with (pre)diabetes.
Electroencephalography (EEG) represents a widely established method for assessing altered and typically developing brain function. However, systematic studies on EEG data quality, its correlates, and consequences are scarce. To address this research gap, the current study focused on the percentage of artifact-free segments after standard EEG pre-processing as a data quality index. We analyzed participant-related and methodological influences, and validity by replicating landmark EEG effects. Further, effects of data quality on spectral power analyses beyond participant-related characteristics were explored. EEG data from a multicenter ADHD-cohort (age range 6 to 45 years), and a non-ADHD school-age control group were analyzed (ntotal = 305). Resting-state data during eyes open, and eyes closed conditions, and task-related data during a cued Continuous Performance Task (CPT) were collected. After pre-processing, general linear models, and stepwise regression models were fitted to the data. We found that EEG data quality was strongly related to demographic characteristics, but not to methodological factors. We were able to replicate maturational, task, and ADHD effects reported in the EEG literature, establishing a link with EEG-landmark effects. Furthermore, we showed that poor data quality significantly increases spectral power beyond effects of maturation and symptom severity. Taken together, the current results indicate that with a careful design and systematic quality control, informative large-scale multicenter trials characterizing neurophysiological mechanisms in neurodevelopmental disorders across the lifespan are feasible. Nevertheless, results are restricted to the limitations reported. Future work will clarify predictive value.
Coagulation factor XIII (FXIII) is a protransglutaminase which plays an important role in clot stabilization and composition by cross-linking the α- and γ-chains of fibrin and increasing the resistance of the clot to mechanical and proteolytic challenges. In this study, we selected six DNA aptamers specific for activated FXIII (FXIIIa) and investigated the functional characterization of FXIIIa after aptamer binding. One of these aptamers, named FA12, efficiently captures FXIIIa even in the presence of zymogenic FXIII subunits. Furthermore, this aptamer inhibits the incorporation of FXIII and α2-antiplasmin (α2AP) into fibrin(ogen) with IC50-values of 38 nM and 17 nM, respectively. In addition to FA12, also another aptamer, FA2, demonstrated significant effects in plasma-based thromboelastometry (rotational thromboelastometry analysis, ROTEM)-analysis where spiking of the aptamers into plasma decreased clot stiffness and elasticity (p < 0.0001). The structure–function correlations determined by combining modeling/docking strategies with quantitative in vitro assays revealed spatial overlap of the FA12 binding site with the binding sites of two FXIII substrates, fibrinogen and α2AP, while FA2 binding sites only overlap those of fibrinogen. Taken together, these features especially render the aptamer FA12 as an interesting candidate molecule for the development of FXIIIa-targeting therapeutic strategies and diagnostic assays.
Simple Summary: Children with acute myeloid leukemia (AML) experience high relapse rates of about 30%; still, survival rates following the first relapse are encouraging. Hence, it is critically important to examine the consequences of a second relapse; however, little is known about this subgroup of patients. This retrospective population-based analysis intends to describe response, survival and prognostic factors relevant for the survival of children with second relapse of AML. Treatment approaches include many different therapeutic regimens, including palliation and intensive treatment with curative intent (63% of the patients). Survival is poor; however, patients who respond to reinduction attempts can be rescued with subsequent hematopoietic stem cell transplantation. We deciphered risk factors, such as short time interval from first to second relapse below one year as being associated with a poor outcome. This analysis will help to improve future international treatment planning and patient care of children with advanced AML.
Abstract: Successful management of relapse is critical to improve outcomes of children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second relapse of AML. Among 1222 pediatric patients of the population-based AML-Berlin–Frankfurt–Munster (BFM) study group (2004 until 2017), 73 patients met the quality parameters for inclusion in this study. Central review of source documentation warranted the accuracy of reported data. Treatment approaches included palliation in 17 patients (23%), intensive therapy with curative intent (n = 46, 63%) and other regimens (n = 10). Twenty-five patients (35%) received hematopoietic stem cell transplantation (HSCT), 21 of whom (88%) had a prior HSCT. Survival was poor, with a five-year probability of overall survival (pOS) of 15 ± 4% and 31 ± 9% following HSCT (n = 25). Early second relapse (within one year after first relapse) was associated with dismal outcome (pOS 2 ± 2%, n = 44 vs. 33 ± 9%, n = 29; p < 0.0001). A third complete remission (CR) is required for survival: 31% (n = 14) of patients with intensive treatment achieved a third CR with a pOS of 36 ± 13%, while 28 patients (62%) were non-responders (pOS 7 ± 5%). In conclusion, survival is poor but possible, particularly after a late second relapse and an intensive chemotherapy followed by HSCT. This analysis provides a baseline for future treatment planning.
Simple Summary: The incidence of brain metastases from breast cancer is increasing and the treatment is still a major challenge. Several scores have been developed in order to estimate the prognosis of patients with brain metastases by objective criteria. Here, we validated all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer patients with brain metastases in the Brain Metastases in the German Breast Cancer (BMBC) registry. Although all three available GPA-scores were associated with OS, they all show limitations mainly in predicting short-term (below 3 months) survival but also in long-term (above 12 months) survival. We discuss the test performances of all scores in our work and provide evidence how physicians should use them as a tool to select patients for different treatment options.
Abstract: Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis (p < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
(2021)
Simple Summary: Prostate carcinoma (PCa) is the most common tumor in men with an increasing age-associated risk. Several therapy strategies, one of which is docetaxel (DX) chemotherapy, have been established. However, due to the development of therapy resistance, in which chemotherapy no longer effectively combats the cancer, advanced, metastasized PCa with a poor prognosis may become manifested and therapy inevitably fails. Thus, new treatment options are urgently needed. Shikonin (SHI), from Traditional Chinese Medicine, has revealed promising antitumor activity in several tumor entities. In the current study, the impact of SHI on four therapy-sensitive and four respective DX-resistant PCa cell lines was determined. SHI induced growth inhibition mainly by necroptosis, a type of cell death, in all the tested therapy-sensitive, but more importantly, DX-resistant PCa cell lines. Corresponding molecular alterations contributing to growth inhibition after SHI exposure were found. SHI could, therefore, be a promising additive in treating advanced PCa.
Abstract: The prognosis for advanced prostate carcinoma (PCa) remains poor due to development of therapy resistance, and new treatment options are needed. Shikonin (SHI) from Traditional Chinese Medicine has induced antitumor effects in diverse tumor entities, but data related to PCa are scarce. Therefore, the parental (=sensitive) and docetaxel (DX)-resistant PCa cell lines, PC3, DU145, LNCaP, and 22Rv1 were exposed to SHI [0.1–1.5 μM], and tumor cell growth, proliferation, cell cycling, cell death (apoptosis, necrosis, and necroptosis), and metabolic activity were evaluated. Correspondingly, the expression of regulating proteins was assessed. Exposure to SHI time- and dose-dependently inhibited tumor cell growth and proliferation in parental and DX-resistant PCa cells, accompanied by cell cycle arrest in the G2/M or S phase and modulation of cell cycle regulating proteins. SHI induced apoptosis and more dominantly necroptosis in both parental and DX-resistant PCa cells. This was shown by enhanced pRIP1 and pRIP3 expression and returned growth if applying the necroptosis inhibitor necrostatin-1. No SHI-induced alteration in metabolic activity of the PCa cells was detected. The significant antitumor effects induced by SHI to parental and DX-resistant PCa cells make the addition of SHI to standard therapy a promising treatment strategy for patients with advanced PCa.
Vascular biotransformation of organic nitrates is independent of cytochrome P450 monooxygenases
(2021)
Background and Purpose: Organic nitrates such as nitroglycerin (NTG) or pentaerythritol tetranitrate (PETN) have been used for over a century in the treatment of angina or ischaemic heart disease. These compounds are prodrugs which release their nitrovasodilators upon enzymic bioactivation by aldehyde dehydrogenase (ALDH2) or cytochromes P450 (CYP). Whereas ALDH2 is known to directly activate organic nitrates in vessels, the contribution of vascular CYPs is unknown and was studied here.
Experimental Approach: As all CYPs depend on cytochrome P450 reductase (POR) as electron donor, we generated a smooth muscle cell-specific, inducible knockout mouse of POR (smcPOR−/−) to investigate the contribution of POR/CYP to vascular biotransformation of organic nitrates.
Key Results: Microsomes containing recombinant CYPs expressed in human vascular tissues released nitrite from NTG and PETN with CYP2C9 and CYP2C8 being most efficient. SFK525, a CYP suicide inhibitor, blocked this effect. smcPOR−/− mice exhibited no obvious cardiovascular phenotype (normal cardiac weight and endothelium-dependent relaxation) and plasma and vascular nitrite production was similar to control (CTL) animals. NTG- and PETN-induced relaxation of isolated endothelium-intact or endothelium-denuded vessels were identical between CTL and smcPOR−/−. Likewise, nitrite release from organic nitrates in aortic rings was not affected by deletion of POR in smooth muscle cells (SMCs). In contrast, inhibition of ALDH2 by benomyl (10 μM) inhibited NTG-induced nitrite production and relaxation. Deletion of POR did not modulate this response.
Conclusions and Implications: Our data suggest that metabolism by vascular CYPs does not contribute to the pharmacological function of organic nitrates.
Parent ratings are often used for screening during the diagnostic evaluation of anxiety disorders. Clinically, it is important to correctly differentiate between anxiety and other psychiatric disorders and to distinguish specific anxiety disorders. The present study examined the validity of the screening results obtained by the Parent Questionnaire for Anxiety and Obsessive-Compulsive Disorders (FBB-ANZ). We exam- ined whether the FBB-ANZ discriminated (1) anxiety and other psychiatric disorders and (2) specific anxiety disorders in children and adoles- cents using ROC analyses. 972 parents of 4;00–11;11-year-old children and 12;00–17;11-year-old adolescents with anxiety disorders, depres- sive episodes, or externalizing disorders completed the FBB-ANZ. Discrimination of anxiety disorders and externalizing disorders in children (AUC = .72) and adolescents (AUC = .76) as well as depressive episodes in children (AUC = .77) was moderate. Good discrimination of different anxiety disorders was found only for separation anxiety in children (AUC = .84) and adolescents (AUC = .87). The results indicate the limited di- agnostic benefit of parent ratings for discriminating different anxiety disorders in children and adolescents. Potential explanations for the re- sults are critically discussed.
Lower leg fractures in children and adolescents - comparison of conservative vs. ECMES treatment
(2021)
Background: Lower leg fractures are one of the most common fractures in pediatric age. In general, treatment of lower leg fractures is predominantly non-operative, requiring clinical and radiological controls. Nevertheless, it can be observed that in recent years tibial shaft fractures have increasingly been treated surgically. The aim of the present study is to investigate treatment strategies in the context of different fracture types of the lower leg Methods: In this retrospective chart review, we analyzed 168 children with a diaphyseal fracture of the lower leg admitted to a trauma center between 2005 and 2017. The fractures were classified according to the AO Pediatric Comprehensive Classification of Long Bone Fractures (AO-PCCF). Results: The frequency of fractures based on the AO-PCCF classification was as follows: Simple oblique fracture of the tibia (43.5%, n = 73), hereof 32 toddler's fractures, multifragmentary oblique fracture of the tibia in 14.3% (n = 24) and simple oblique fracture of both, tibia and fibula in 18 patients (10.7%). Most pediatric fractures were treated conservatively by cast (n = 125). Thirty-seven patients received an ECMES, whereas 3 patients were treated with an external fixator and also 3 fractures were stabilized by plate osteosynthesis. Conservatively treated patients were significantly younger (mean age 6.0) compared to patients treated with ECMES (mean age 10.2) or plate osteosynthesis (PO)/external fixator (EF) (mean age 11.3), even if toddler's fractures (mean age 2.0) are excluded (mean age 7.4). There was no difference in time to full weight-bearing, hospitalization of patients treated with ECMES compared to conservative therapy although ECMES-treated fractures show more instability. The consolidation time was significantly higher in ECMES treated patients compared to conservative therapy. Conclusion: Pediatric patients (≤4 years) with lower leg fractures most often showed simple oblique fractures of the tibia, half of them toddler's fractures, which were treated predominantly by conservative therapy. All in all, the consolidation time was longer in intramedullary nailing (ECMES) than in conservative therapy. Nevertheless, time to full weight bearing and duration of cast was the same in both groups, even though ECMES treated fractures show more instability.
Background: The alpha7 nicotinic acetylcholine receptor (Chrna7) plays an essential anti-inflammatory role in immune homeostasis and was recently found on mast cells (MC). Psychosocial stress can trigger MC hyperactivation and increases pro-inflammatory cytokines in target tissues such as the skin. If the cholinergic system (CS) and Chrna7 ligands play a role in these cascades is largely unknown. Objective: To elucidate the role of the CS in the response to psychosocial stress using a mouse-model for stress-triggered cutaneous inflammatory circuits. Methods: Key CS markers (ACh, Ch, SLURP-1, SLURP-2, Lynx1, Chrm3, Chrna7, Chrna9, ChAT, VAChT, Oct3, AChE, and BChE) in skin and its MC (sMC), MC activation, immune parameters (TNFα, IL1β, IL10, TGFβ, HIF1α, and STAT3) and oxidative stress were analyzed in skin from 24 h noise-stressed mice and in cultured MC (cMC) from C57BL/6 or Chrna7-Knockout mice. Results: First, Chrna7 and SLURP-1 mRNA were exclusively upregulated in stressed skin. Second, histomorphometry located Chrna7 and SLURP-1 in nerves and sMC and demonstrated upregulated contacts and increased Chrna7+ sMC in stressed skin, while 5 ng/mL SLURP-1 degranulated cMC. Third, IL1β+ sMC were high in stressed skin, and while SLURP-1 alone had no significant effect on cMC cytokines, it upregulated IL1β in cMC from Chrna7-KO and in IL1β-treated wildtype cMC. In addition, HIF1α+ sMC were high in stressed skin and Chrna7-agonist AR-R 17779 induced ROS in cMC while SLURP-1 upregulated TNFα and IL1β in cMC when HIF1α was blocked. Conclusions: These data infer that the CS plays a role in the regulation of stress-sensitive inflammatory responses but may have a surprising pro-inflammatory effect in healthy skin, driving IL1β expression if SLURP-1 is involved.
Complement has been considered as an important factor impacting the host–pathogen association of spirochetes belonging to the Borrelia burgdorferi sensu lato complex, and may play a role in the spirochete’s ecology. Birds are known to be important hosts for ticks and in the maintenance of borreliae. Recent field surveys and laboratory transmission studies indicated that certain avian species act as reservoir hosts for different Borrelia species. Nevertheless, our current understanding of the molecular mechanisms determining host tropism of Borrelia is still in its fledgling stage. Concerning the role of complement in avian-host tropism, only a few bird species and Borrelia species have been analysed so far. Here, we performed in vitro serum bactericidal assays with serum samples collected from four bird species including the European robin Erithacus rubecula, the great tit Parus major, the Eurasian blackbird Turdus merula, and the racing pigeon Columba livia, as well as four Borrelia species (B. afzelii, B. garinii, B. valaisiana, and B. burgdorferi sensu stricto). From July to September 2019, juvenile wild birds were caught using mist nets in Portugal. Racing pigeons were sampled in a loft in October 2019. Independent of the bird species analysed, all Borrelia species displayed an intermediate serum-resistant or serum-resistant phenotype except for B. afzelii challenged with serum from blackbirds. This genospecies was efficiently killed by avian complement, suggesting that blackbirds served as dead-end hosts for B. afzelii. In summary, these findings suggest that complement contributes in the avian–spirochete–tick infection cycle and in Borrelia-host tropism.
Background: To investigate patients’ perspectives on polypharmacy and the use of a digital decision support system to assist general practitioners (GPs) in performing medication reviews. Methods: Qualitative interviews with patients or informal caregivers recruited from participants in a cluster-randomized controlled clinical trial (cRCT). The interviews were transcribed verbatim and analyzed using thematic analysis. Results: We conducted 13 interviews and identified the following seven themes: the patients successfully integrated medication use in their everyday lives, used medication plans, had both good and bad personal experiences with their drugs, regarded their healthcare providers as the main source of medication-related information, discussed medication changes with their GPs, had trusting relationships with them, and viewed the use of digital decision support tools for medication reviews positively. No unwanted adverse effects were reported. Conclusions: Despite drug-related problems, patients appeared to cope well with their medications. They also trusted their GPs, despite acknowledging polypharmacy to be a complex field for them. The use of a digital support system was appreciated and linked to the hope that reasons for selecting specific medication regimens would become more comprehensible. Further research with a more diverse sampling might add more patient perspectives.
Background: To assess the potential of radiomic features to quantify components of blood in intraaortic vessels to non-invasively predict moderate-to-severe anemia in non-contrast enhanced CT scans. Methods: One hundred patients (median age, 69 years; range, 19–94 years) who received CT scans of the thoracolumbar spine and blood-testing for hemoglobin and hematocrit levels ± 24 h between 08/2018 and 11/2019 were retrospectively included. Intraaortic blood was segmented using a spherical volume of interest of 1 cm diameter with consecutive radiomic analysis applying PyRadiomics software. Feature selection was performed applying analysis of correlation and collinearity. The final feature set was obtained to differentiate moderate-to-severe anemia. Random forest machine learning was applied and predictive performance was assessed. A decision-tree was obtained to propose a cut-off value of CT Hounsfield units (HU). Results: High correlation with hemoglobin and hematocrit levels was shown for first-order radiomic features (p < 0.001 to p = 0.032). The top 3 features showed high correlation to hemoglobin values (p) and minimal collinearity (r) to the top ranked feature Median (p < 0.001), Energy (p = 0.002, r = 0.387), Minimum (p = 0.032, r = 0.437). Median (p < 0.001) and Minimum (p = 0.003) differed in moderate-to-severe anemia compared to non-anemic state. Median yielded superiority to the combination of Median and Minimum (p(AUC) = 0.015, p(precision) = 0.017, p(accuracy) = 0.612) in the predictive performance employing random forest analysis. A Median HU value ≤ 36.5 indicated moderate-to-severe anemia (accuracy = 0.90, precision = 0.80). Conclusions: First-order radiomic features correlate with hemoglobin levels and may be feasible for the prediction of moderate-to-severe anemia. High dimensional radiomic features did not aid augmenting the data in our exemplary use case of intraluminal blood component assessment.
Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to erlotinib as a model of acquired drug resistance. Constitutive CIP2A resulted in a constitutive activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce CIP2A levels, which resulted in an activation of protein phosphatase 2A and deactivation of Akt. Combination experiments with erlotinib and bortezomib revealed a lack of interaction between the two drugs. However, the effect size of bortezomib was higher in HCC4006rErlo0.5, compared to the erlotinib-sensitive HCC4006 cells, as indicated by an increase in Emax (0.911 (95%CI 0.867–0.954) vs. 0.585 (95%CI 0.568–0.622), respectively) and decrease in EC50 (52.4 µM (95%CI 46.1–58.8 µM) vs. 73.0 µM (95%CI 60.4–111 µM), respectively) in the concentration–effect model, an earlier onset of cell death induction, and a reduced colony surviving fraction (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively, n = 3, p < 0.05). Therefore, modulation of CIP2A with bortezomib could be an interesting approach to overcome drug resistance to erlotinib treatment in NSCLC.
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.
Treatment options of locoregional recurrent head and neck squamous cell cancer (HNSCC) include both local strategies as surgery or re-radiotherapy and systemic therapy. In this prospective, multi-center, non-interventional study, patients were treated either with platinum-based chemotherapy and cetuximab (CT + Cet) or re-radiotherapy and cetuximab (RT + Cet). In the current analysis, progression-free survival (PFS) and overall survival (OS) were compared in patients with locoregional recurrence. Four hundred seventy patients were registered in 97 German centers. After exclusion of patients with distant metastases, a cohort of 192 patients was analyzed (129 CT + Cet, 63 RT + Cet). Radiotherapy was delivered as re-irradiation to 70% of the patients. The mean radiation dose was 51.8 Gy, whereas a radiation dose of ≥60 Gy was delivered in 33% of the patients. Chemotherapy mainly consisted of cisplatin/5-flurouracil (40%) or carboplatin/5-flurouracil (29%). The median PFS was 9.2 months in the RT + Cet group versus 5.1 months in the CT + Cet group (hazard ratio for disease progression or death, 0.40, 95% CI, 0.27–0.57, p < 0.0001). Median OS was 12.8 months in the RT + Cet group versus 7.9 months in the CT + Cet group (hazard ratio for death, 0.50, 95% CI, 0.33–0.75, p = 0.0008). In conclusion, radiotherapy combined with cetuximab improved survival compared to chemotherapy combined with cetuximab in locally recurrent HNSCC.
Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
Background: A major disadvantage of current spacers for two-stage revision total knee arthroplasty (R-TKA) is the risk of (sub-) luxation during mobilization in the prosthesis-free interval, limiting their clinical success with detrimental consequences for the patient. The present study introduces a novel inverse spacer, which prevents major complications, such as spacer (sub-) luxations and/or fractures of spacer or bone. Methods: The hand-made inverse spacer consisted of convex tibial and concave femoral components of polymethylmethacrylate bone cement and was intra-operatively molded under maximum longitudinal tension in 5° flexion and 5° valgus position. Both components were equipped with a stem for rotational stability. This spacer was implanted during an R-TKA in 110 knees with diagnosed or suspected periprosthetic infection. Postoperative therapy included a straight leg brace and physiotherapist-guided, crutch-supported mobilization with full sole contact. X-rays were taken before and after prosthesis removal and re-implantation. Results: None of the patients experienced (sub-) luxations/fractures of the spacer, periprosthetic fractures, or soft tissue compromise requiring reoperation. All patients were successfully re-implanted after a prosthesis-free interval of 8 weeks, except for three patients requiring an early exchange of the spacer due to persisting infection. In these cases, the prosthetic-free interval was prolonged for one week. Conclusion: The inverse spacer in conjunction with our routine procedure is a safe and cost-effective alternative to other articulating or static spacers, and allows crutch-supported sole contact mobilization without major post-operative complications. Maximum longitudinal intra-operative tension in 5° flexion and 5° valgus position appears crucial for the success of surgery.
Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12 months after treatment initiation for the early identification of high-risk patients with inadequate treatment responses who may require treatment modification. However, there are only very limited data concerning the real-world clinical management of patients with PBC in Germany. Objective: The aim of this retrospective multicenter study was to evaluate response rates to standard first-line UDCA therapy and subsequent Second-line treatment regimens in a large cohort of well-characterized patients with PBC from 10 independent hepatological referral centers in Germany prior to the introduction of obeticholic acid as a licensed second-line treatment option. Methods: Diagnostic confirmation of PBC, standard first-line UDCA treatment regimens and response rates at 12 months according to Paris-I, Paris-II, and Barcelona criteria, the follow-up cut-off alkaline phosphatase (ALP) ≤ 1.67 × upper limit of normal (ULN) and the normalization of bilirubin (bilirubin ≤ 1 × ULN) were retrospectively examined between June 1986 and March 2017. The management and hitherto applied second-line treatment regimens in patients with an inadequate response to UDCA and subsequent response rates at 12 months were also evaluated. Results: Overall, 480 PBC patients were included in this study. The median UDCA dosage was 13.2 mg UDCA/kg bodyweight (BW)/d. Adequate UDCA treatment response rates according to Paris-I, Paris-II, and Barcelona criteria were observed in 91, 71.3, and 61.3% of patients, respectively. In 83.8% of patients, ALP ≤ 1.67 × ULN were achieved. A total of 116 patients (24.2%) showed an inadequate response to UDCA according to at least one criterion. The diverse second-line treatment regimens applied led to significantly higher response rates according to Paris-II (35 vs. 60%, p = 0.005), Barcelona (13 vs. 34%, p = 0.0005), ALP ≤ 1.67 × ULN and bilirubin ≤ 1 × ULN (52.1 vs. 75%, p = 0.002). The addition of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II: 24 vs. 74%, p = 0.004; Barcelona: 50 vs. 84%, p = 0.046; ALP < 1.67 × ULN and bilirubin ≤ 1 × ULN: 33 vs. 86%, p = 0.001). Conclusion: Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modification significantly increases subsequent response rates of these patients.
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs.
Simple Summary: Tooth roots are increasingly applied for bone reconstruction before implant placement. Growth factors stored in the dentin are assumed to enhance bone regeneration, however, the evidence is low. To this aim, collagen membranes were coated with dentin lysates obtained from extracted porcine teeth or remain untreated. The collagen membranes were tested for their capacity to stimulate bone formation in rat calvarial bone defects. After four weeks of healing, micro-computed tomography and histological analyses revealed that dentin lysates coating had no significant impact on the rather strong bone regeneration reaching a nearly complete defect closure even in untreated defects. It can thus be concluded that dentin lysates do not hinder bone regeneration. Conclusions concerning a possible stimulation of bone regeneration by dentin lysates should not be drawn.
Abstract: Autogenous tooth roots are increasingly applied as a grafting material in alveolar bone augmentation. Since tooth roots undergo creeping substitution similar to bone grafts, it can be hypothesized that osteoclasts release the growth factors stored in the dentin thereby influencing bone formation. To test this hypothesis, collagen membranes were either soaked in acid dentin lysates (ADL) from extracted porcine teeth or serum–free medium followed by lyophilization. Thereafter, these membranes covered standardized 5-mm-diameter critical-size defects in calvarial bone on rats. After four weeks of healing, micro-computed tomography and histological analyses using undecalcified thin ground sections were performed. Micro-computed tomography of the inner 4.5 mm calvaria defects revealed a median bone defect coverage of 91% (CI: 87–95) in the ADL group and 94% (CI: 65–100) in the control group, without significant differences between the groups (intergroup p > 0.05). Furthermore, bone volume (BV) was similar between ADL group (5.7 mm3, CI: 3.4–7.1) and control group (5.7 mm3, CI: 2.9–9.7). Histomorphometry of the defect area confirmed these findings with bone area values amounting to 2.1 mm2 (CI: 1.2–2.6) in the ADL group and 2.0 mm2 (CI: 1.1–3.0) in the control group. Together, these data suggest that acid dentin lysate lyophilized onto collagen membranes failed to modulate the robust bone formation when placed onto calvarial defects.
The rapid detection of pathogens in infected wounds can significantly improve the clinical outcome. Wound exudate, which can be collected in a non-invasive way, offers an attractive sample material for the detection of pathogens at the point-of-care (POC). Here, we report the development of a nucleic acid lateral flow immunoassay for direct detection of isothermally amplified DNA combined with fast sample preparation. The streamlined protocol was evaluated using human wound exudate spiked with the opportunistic pathogen Pseudomonas aeruginosa that cause severe health issues upon wound colonization. A detection limit of 2.1 × 105 CFU per mL of wound fluid was achieved, and no cross-reaction with other pathogens was observed. Furthermore, we integrated an internal amplification control that excludes false negative results and, in combination with the flow control, ensures the validity of the test result. The paper-based approach with only three simple hands-on steps has a turn-around time of less than 30 min and covers the complete analytical process chain from sample to answer. This newly developed workflow for wound fluid diagnostics has tremendous potential for reliable pathogen POC testing and subsequent target-oriented therapy.
Causality assessment in liver injury induced by drugs and herbs remains a debated issue, requiring innovation and thorough understanding based on detailed information. Artificial intelligence (AI) principles recommend the use of algorithms for solving complex processes and are included in the diagnostic algorithm of Roussel Uclaf Causality Assessment Method (RUCAM) to help assess causality in suspected cases of idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI). From 1993 until the middle of 2020, a total of 95,865 DILI and HILI cases were assessed by RUCAM, outperforming by case numbers any other causality assessment method. The success of RUCAM can be traced back to its quantitative features with specific data elements that are individually scored leading to a final causality grading. RUCAM is objective, user friendly, transparent, and liver injury specific, with an updated version that should be used in future DILI and HILI cases. Support of RUCAM was also provided by scientists from China, not affiliated to any network, in the results of a scientometric evaluation of the global knowledge base of DILI. They highlighted the original RUCAM of 1993 and their authors as a publication quoted the greatest number of times and ranked first in the category of the top 10 references related to DILI. In conclusion, for stakeholders involved in DILI and HILI, RUCAM seems to be an effective diagnostic algorithm in line with AI principles.
The aim of this study was to evaluate the clinical and microbiological effects of subgingival instrumentation (SI) alone or combined with either local drug delivery (LDD) or photodynamic therapy (PDT) in persistent/recurrent pockets in patients enrolled in supportive periodontal therapy (SPT). A total of 105 patients enrolled in SPT were randomly treated as follows: group A (n = 35): SI +PDT and 7 days later 2nd PDT; group B (n = 35): SI+LDD; group C (n = 35): SI (control). Prior intervention, at 3 and 6 months after therapy, probing pocket depths, clinical attachment level, number of treated sites with bleeding on probing (n BOP), full mouth plaque and bleeding scores (gingival bleeding index, %BOP) were recorded. At the same time points, 8 periodontopathogens were quantitatively determined. All three treatments resulted in statistically significant improvements (p < 0.05) of all clinical parameters without statistically significant intergroup differences (p > 0.05). Several bacterial species were reduced in both test groups, with statistically significantly higher reductions for LDD compared to PDT and the control group. In conclusion, the present data indicate that: (a) In periodontal patients enrolled in SPT, treatment of persistent/recurrent pockets with SI alone or combined with either PDT or LDD may lead to comparable clinical improvements and (b) the adjunctive use of LDD appears to provide better microbiological improvements for some periodontal pathogens than SI alone or combined with PDT.
Simple Summary: Renal insufficiency is frequently seen in newly diagnosed multiple myeloma and can be due to the disease itself but also caused by medical interventions or infections. Patients with severe renal insufficiency are known to have an adverse prognosis, but recently, it was shown that even moderately impaired kidney function can have long-term sequelae. Achieving quick disease control by effective antimyeloma therapy can lead to the recovery of renal function. We investigated the kidney-specific variables in a large cohort of 770 myeloma patients receiving three different three-drug regimens for initial myeloma treatment to learn more about the differential effects on kidney function in an early disease phase. All regimens had a positive impact on kidney function without a difference in the proportion of patients who reached normal renal function after three cycles. Interestingly, patients who received bortezomib, lenalidomide, and dexamethasone tended to have higher risk for a worse renal function following induction when compared to the initial values.
Abstract: Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.
Simple Summary: Forensic entomologists are most often tasked with determining when arthropods colonized living or deceased vertebrates. In most cases, this estimation involves humans; however, pets, livestock, and other domesticated animals can also be illegally killed or victims of neglect. Globally, there is no standard format for the case report, and much of the content is based on the personal preferences of the analyst or standards set within a country. The article below proposes a general overview of sections to be considered when drafting a case report.
Abstract: Forensic practitioners analyzing entomological evidence are faced with numerous challenges when presenting their findings to law practitioners, particularly in terms of terminology used to describe insect age, what this means for colonization time of remains, and the limitations to estimates made. Due to varying legal requirements in different countries, there is no standard format for the entomological case report prepared, nor any guidelines as to the sections that are required, optional or unnecessary in a case report. The authors herein propose sections that should be considered when drafting an entomological case report. The criteria under which entomological evidence is analyzed are discussed, as well as the limitations for each criterion. The concept of a global, standardized entomological case report is impossible to achieve due to national legislative differences, but the authors here propose a basic template which can be adapted and changed according to the needs of the practitioner. Furthermore, while the discussion is fairly detailed, capturing all differences between nations could not be accomplished, and those initiating casework for the first time are encouraged to engage other practicing forensic entomologists or professional associations within their own nation or region, to ensure a complete report is generated that meets lab or national requirements, prior to generating a finalized report.
Tumor antigen-specific redirection of cytotoxic T cells (CTLs) or natural killer (NK) cells including chimeric antigen receptor (CAR-) and T cell receptor (TCR-) cell therapy is currently being evaluated in different tumor entities including melanoma. Expression of melanoma-specific antigen recognized by the respective CAR or TCR directly or presented by HLA molecules is an indispensable prerequisite for this innovative therapy. In this study, we investigated in 168 FFPE tumor specimens of patients with stage I-IV melanoma the protein expression of HER2, TRP2, ABCB5, gp100, p53, and GD2 by immunohistochemistry (IHC). These results were correlated with clinical parameters. Membrane expression of HER2 and GD2 was also investigated in ten melanoma cell lines by flow cytometry for which corresponding tumors were analyzed by IHC. Our results demonstrated that gp100 was the most frequently overexpressed protein (61%), followed by TRP2 (50%), GD2 (38%), p53 (37%), ABCB5 (17%), and HER2 (3%). TRP2 expression was higher in primary tumors compared to metastases (p = 0.005). Accordingly, TRP2 and ABCB5 expression was significantly associated with lower tumor thickness of the primary (p = 0.013 and p = 0.025). There was no association between protein expression levels and survival in advanced melanoma patients. Flow cytometric analysis revealed abundant surface expression of GD2 and HER2 in all melanoma cell lines. The discordant HER2 expression in situ and in vitro suggests a tissue culture associated induction. In summary, our data support the use of gp100 and GD2 as a potential target for developing engineered TCR- or CAR-cell therapies, respectively, against melanoma.
Simple Summary: Currently, it is unclear which kind of axillary staging surgery breast cancer patients with lymph node metastasis should receive after neoadjuvant chemotherapy. For decades, these patients have been treated with a full axillary lymph node dissection, even if they converted to clinical node negativity. However, the removal of a large number of lymph nodes during the procedure can increase arm morbidity and impact quality of life. Therefore, several studies investigated less radical surgical strategies in this setting, such as sentinel lymph node biopsy or targeted axillary dissection, i.e., removal of a previously marked node combined with sentinel node removal. In this review, we summarize current evidence on the different surgical techniques and compare national and international recommendations. We show that many questions regarding oncological safety of different surgery types and the optimal marking technique remain unanswered and present the multinational prospective cohort study AXSANA that will address these open issues.
Abstract: In the last two decades, surgical methods for axillary staging in breast cancer patients have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the optimal management remains unclear. Current guidelines vary widely, endorsing different strategies. We performed a literature review on axillary staging strategies and their place in international recommendations. This overview defines knowledge gaps associated with specific procedures, summarizes currently ongoing clinical trials that address these unsolved issues, and provides the rationale for further research. While some guidelines have already implemented surgical de-escalation, replacing ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+ patients converting to clinical node negativity, others recommend ALND. Numerous techniques are in use for tagging lymph node metastasis, but many questions regarding the marking technique, i.e., the optimal time for marker placement and the number of marked nodes, remain unanswered. The optimal number of SLNs to be excised also remains a matter of debate. Data on oncological safety and quality of life following different staging procedures are lacking. These results provide the rationale for the multinational prospective cohort study AXSANA initiated by EUBREAST, which started enrollment in June 2020 and aims at recruiting 3000 patients in 20 countries (NCT04373655; Funded by AGO-B, Claudia von Schilling Foundation for Breast Cancer Research, AWOgyn, EndoMag, Mammotome, and MeritMedical).
The pathophysiological role of neural autoantibodies in acute psychotic disorders is receiving increased attention. However, there is still an ongoing debate, whether predominantly psychotic manifestations of autoimmune encephalitides exist that may remain undetected and, thus, untreated. Furthermore, it is discussed if such conditions can be diagnosed based on serum antibody results or if a reliable diagnosis requires additional cerebrospinal fluids (CSF) results. In this study, we screened pairs of serum and CSF samples from antipsychotic-naïve individuals with first-episode schizophrenic psychosis (FEP, n = 103), clinical high risk for psychosis (CHR, n = 47), and healthy volunteers (HV, n = 40) for eight different antibodies against various antigens that have been shown to be associated with autoimmune encephalitides: N-methyl-D-aspartate receptor (NMDAR, NR1 subunits only), glutamic acid decarboxylase (GAD65), leucine-rich glioma inactivated protein 1 (LGI1), contactin-associated protein-like 2 protein (CASPR2), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subunit 1, AMPAR subunit 2, γ-aminobutyric acid-B receptors (GABABR), and glycine receptors. All patients were within the norm with regards to a careful neurological examination, a magnetic resonance imaging (MRI) of the brain, an electroencephalogram (EEG), and routine blood pathology. All CSF samples were autoantibody-negative. In three serum samples of individuals with FEP, we detected low-titer CASPR2 immunoglobulin (Ig) G antibodies (≤1:160, n = 2) and non-IgG antibodies against NMDAR (n = 1) (overall serum-autoantibody prevalence in FEP: 2.91%). However, the IgG titers were below the laboratory cut-off defined for positivity, and non-IgG antibodies are of no clinical relevance. This suggests that there were no cases of autoimmune encephalitis in our cohort. Our results highlight the importance and the high specificity of CSF analysis to reliably detect autoantibodies. They confirm the hypothesis that pure psychotic manifestations of antibody-associated autoimmune encephalitides without any additional neuropsychiatric findings are very rare. However, special attention must be paid to those presenting with atypical mental illnesses with additional neurological symptoms, evidence of clinically-significant cognitive involvement, profound sleep-wake perturbations, seizures, electroencephalographic, or magnetic resonance imaging pathologies to be able to identify cases with autoimmune-mediated psychiatric syndromes.
Background: Treatment of first-time shoulder dislocation (FSD) is a topic of debate. After high rates of recurrent instability after nonoperative management were reported in the literature, primary repair of FSD significantly increased. At the same time, new concepts were proposed that had promising results for immobilization in external rotation (ER) and abduction (ABD). Purpose: The aim of this study was to evaluate the recurrence rates (primary outcome) and clinical outcomes (secondary outcome parameters) of immobilization in ER+ABD versus arthroscopic primary stabilization after FSD. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: In a multicenter randomized controlled trial, patients with FSD were randomized to either treatment with immobilization in 60° of ER plus 30° of ABD (group 1) or surgical treatment with arthroscopic Bankart repair (group 2). Clinical evaluation was performed 1, 3, and 6 weeks as well as 6, 12, and 24 months postoperatively or after reduction, including range of motion, instability testing, subjective shoulder value, Constant-Murley score, Rowe score, and Western Ontario Shoulder Instability Index. Recurrent instability events were prospectively recorded. Results: Between 2011 and 2017, a total of 112 patients were included in this study. Of these, 60 patients were allocated to group 1 and 52 to group 2. At the 24-month follow-up, 91 patients (81.3%) were available for clinical examination. The recurrence rate was 19.1% in group 1 and 2.3% in group 2 (P = .016). No significant differences were found between groups regarding clinical shoulder scores (P > .05). Due to noncompliance with the immobilization treatment protocol, 4 patients (6.7%) were excluded. Conclusion: Immobilization in ER+ABD versus primary arthroscopic shoulder stabilization for the treatment of FSD showed no differences in clinical shoulder scores. However, recurrent instability was significantly higher after nonoperative treatment.
Background: Gan–Dou–Fu–Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis.
Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein–protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR. Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine–cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis. Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD using GDFMD.
Simple Summary: Mutations in RAS-family genes frequently cause different types of human cancers. Inhibitors of the MEK (mitogen-activated protein kinase) and ERK (extracellular signal-regulated kinase) protein kinases that function downstream of RAS proteins have shown some clinical benefits when used for the treatment of these cancers, but drug resistance frequently emerges. Here we show that combined treatment with MEK and ERK inhibitors blocks the emergence of resistance to either drug alone. However, if cancer cells have already developed resistance to MEK inhibitors or to ERK inhibitors, the combined therapy is frequently ineffective. These findings imply that these inhibitors should be used together for cancer therapy. We also show that drug resistance involves complex patterns of rewiring of cellular kinase signaling networks that do not overlap between each different cancer cell line. Nonetheless, we show that MAP4K4 is required for efficient cell proliferation in several different MEK/ERK inhibitor resistant cancer cell lines, uncovering a potential new therapeutic target.
Abstract: Oncogenic mutations in RAS family genes arise frequently in metastatic human cancers. Here we developed new mouse and cellular models of oncogenic HrasG12V-driven undifferentiated pleomorphic sarcoma metastasis and of KrasG12D-driven pancreatic ductal adenocarcinoma metastasis. Through analyses of these cells and of human oncogenic KRAS-, NRAS- and BRAF-driven cancer cell lines we identified that resistance to single MEK inhibitor and ERK inhibitor treatments arise rapidly but combination therapy completely blocks the emergence of resistance. The prior evolution of resistance to either single agent frequently leads to resistance to dual treatment. Dual MEK inhibitor plus ERK inhibitor therapy shows anti-tumor efficacy in an HrasG12V-driven autochthonous sarcoma model but features of drug resistance in vivo were also evident. Array-based kinome activity profiling revealed an absence of common patterns of signaling rewiring in single or double MEK and ERK inhibitor resistant cells, showing that the development of resistance to downstream signaling inhibition in oncogenic RAS-driven tumors represents a heterogeneous process. Nonetheless, in some single and double MEK and ERK inhibitor resistant cell lines we identified newly acquired drug sensitivities. These may represent additional therapeutic targets in oncogenic RAS-driven tumors and provide general proof-of-principle that therapeutic vulnerabilities of drug resistant cells can be identified.
Neurogenic/neuropathic bowel dysfunction (NBD) is common in children who are affected by congenital and acquired neurological disease, and negatively impacts quality of life. In the past, NBD received less attention than neurogenic bladder, generally being considered only in spina bifida (the most common cause of pediatric NBD). Many methods of conservative and medical management of NBD are reported, including relatively recently Transanal Irrigation (TAI). Based on the literature and personal experience, an expert group (pediatric urologists/surgeons/gastroenterologists with specific experience in NBD) focused on NBD in children and adolescents. A statement document was created using a modified Delphi method. The range of causes of pediatric NBD are discussed in this paper. The various therapeutic approaches are presented to improve clinical management. The population of children and adolescents with NBD is increasing, due both to the higher survival rate and better diagnosis. While NBD is relatively predictable in producing either constipation or fecal incontinence, or both, its various effects on each patient will depend on a wide range of underlying causes and accompanying comorbidities. For this reason, management of NBD should be tailored individually with a combined multidisciplinary therapy appropriate for the status of the affected child and caregivers.
Background: Myocardial efficiency should be maintained stable under light-to-moderate stress conditions, but ischemia puts the myocardium at risk for impaired functionality. Additionally, the measurement of such efficiency typically requires invasive heart catheterization and exposure to ionizing radiation. In this work, we aimed to non-invasively assess myocardial power and the resulting efficiency during pharmacological stress testing and ischemia induction. Methods: In a cohort of n = 10 healthy Landrace pigs, dobutamine stress testing was performed, followed by verapamil-induced ischemia alongside cardiac magnetic resonance (CMR) imaging. External myocardial power, internal myocardial power, and myocardial efficiency were assessed non-invasively using geometrical and functional parameters from CMR volumetric as well as blood flow and pressure measurements. Results: External myocardial power significantly increased under dobutamine stress [2.3 (1.6–3.1) W/m2 vs. 1.3 (1.1–1.6) W/m2, p = 0.005] and significantly decreased under verapamil-induced ischemia [0.8 (0.5–0.9) W/m2, p = 0.005]. Internal myocardial power [baseline: 5.9 (4.6–8.5) W/m2] was not affected by dobutamine [7.5 (6.9–9.0) W/m2, p = 0.241] nor verapamil [5.8 (4.7–8.8) W/m2, p = 0.878]. Myocardial efficiency did not change from baseline to dobutamine [21% (15–27) vs. 31% (20–44), p = 0.059] but decreased significantly during verapamil-induced ischemia [10% (8–13), p = 0.005]. Conclusion: In healthy Landrace pigs, dobutamine stress increased external myocardial power, whereas myocardial efficiency was maintained stable. On the contrary, verapamil-induced ischemia substantially decreased external myocardial power and myocardial efficiency. Non-invasive CMR was able to quantify these efficiency losses and might be useful for future clinical studies evaluating the effects of therapeutic interventions on myocardial energetics.